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ABSTRACT
Lisano, Jonathon. Monocyte Phenotype and Whole Blood Immune Response in Physically
Active Chronic Cannabis Users and Non-Users. Published Doctor of Philosophy
dissertation, University of Northern Colorado, 2019.

Some physically active individuals are now advocating for the use of cannabis
with exercise for its potential to optimize the immune response. Yet, it remains to be seen
whether the chronic use of cannabis products is linked to alterations in immune
characteristics, such as monocyte phenotype and function in physically active individuals.
The purpose of this cross-sectional study was to assess resting concentrations of
c-reactive protein (CRP) and interleukin-6 (IL-6), monocyte phenotype and
lipopolysaccharide (LPS) stimulated production of Interleukin-6 (IL-6) following pretreated with synthetic cannabinoid 2 (CB2) receptor agonist and antagonist in physically
active individuals using cannabis products at least 5-times per week for the past 6-months
(CU) compared to physically active individuals who have not used any cannabis products
in the past 6-months (NU).
Physically active participants (N=23; n=11 CU and n=12 NU) completed medical
history, physical activity, and cannabis use surveys prior to assessment of their height,
weight, body mass index (BMI), body fat percentage, resting heart rate and V̇O2max in
their initial visit. In a subsequent visit, intravenous whole blood was collected following a
12-hour fast and 72-hours removed from last bout of vigorous exercise. Isolated serum
was used to determine resting protein concentration of CRP and IL-6. Monocyte
iii

phenotype was analyzed using an Attune NxT flow cytometer following co-staining of
CD-14 and CD-16. Supernatant from whole blood samples diluted with culture medium
and stimulated for 24-hours with LPS following 1-hour pre-treatment with CB2 agonist
and antagonist at a concentration of 1µM. Collected supernatant was analyzed for IL-6
using an ELISA. Data are presented as mean ± SD and were analyzed using SPSS using
unpaired t-tests and ANOVA (α=0.05). Pearson’s correlations were calculated to
determine meaningful relationships between primary outcome variables.
There were no differences between CU and NU with respect to age, height,
weight, BMI, body fat percentage, resting heart rate, or relative V̇O2 max. There were no
differences between the groups with respect to resting concentrations of CRP or IL-6.
Total monocytes per mL of blood was significantly greater in CU (5.08 x 105 ± 1.63 x
105 cells/mL) when compared to NU (3.23 x 105 ± 1.20 x 105 cells/mL) (p = 0.01). The
number of classical (CU: 3.77 x 105 ± 1.36 x 105 cells/mL; NU: 2.56 x 105 ± 0.97 x 105
cells/mL, p=0.02) and intermediate monocytes (CU: 7.29 x 105 ± 5.19 x 105 cells/mL;
NU: 2.32 x 105 ± 2.18 x 105 cells/mL, p=0.01) were significantly greater in CU
compared to NU. Cannabis users had a significantly greater relative percent of
intermediate monocytes (CU: 13.89 ± 8.43%; NU: 6.33 ± 4.91%; p=0.02), but there were
no differences in classical (76.92 ± 8.48 %) or non-classical (12.73 ± 7.14 %) monocytes
between the groups. There were no significant differences in stimulated production of IL6 between CU and NU groups. Further, when the covariates of age, body fat percent, or
monocytes/mL were used, there were no significant differences present between
stimulated IL-6 production.
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Results from this study suggest that the chronic use of cannabis in physically
active individuals may alter monocyte phenotype and count, but this was not related to
changes in resting concentrations of inflammatory markers CRP and IL-6, nor does it
alter whole blood LPS stimulated IL-6 release.
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CHAPTER I
INTRODUCTION TO THE STUDY
Inflammation is the natural response of the body to invasion by a foreign object or
tissue damage. Acute inflammation can last from a few hours to a few days and is
commonly perceived as highly beneficial with minor symptoms of swelling, redness, heat
and mild pain (1). On the other hand, chronic inflammation can result in pathological
development of disease including: type 2 diabetes mellitus (2), cancer (3) and
cardiovascular disease (CVD) (4).
Monocytes are immune cells implicated in the initiation and integration of both
the innate and adaptive immune response and are recognized as key players in the
development and progression of the inflammatory response (1). Monocytes are
circulating precursors to tissue macrophages and dendritic cells and are further subdivided into three separate phenotypes based on their expression of cluster of
determination 14 (CD14) and 16 (CD16) (5). Classical monocytes are the most abundant
sub-population at 85-95% of total monocytes followed by 5-10% non-classical
monocytes and <5% intermediate monocytes (6, 7). Classical monocytes express the
phenotype CD14++/CD16- (5) and are the primary producers of cytokines, like interleukin
6 (IL-6) and tumor necrosis factor α (TNFα) (8, 9). These cytokines are typically secreted
in response to endotoxins, like lipopolysaccharide (LPS), binding to the CD14 and tolllike receptor 4 (TLR4) complex (6). Non-classical monocytes display the phenotype of
CD14+/CD16++ (5) and primarily patrol the vasculature for nucleic acids and viruses
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(48). Finally, intermediate monocytes display functions of both classical and nonclassical monocytes (6, 10) and elevated numbers of these cells are linked to the
development of diseases including CVD (10, 11).
There are several biomarkers commonly used in both basic science and clinical
environments to characterize the inflammatory status of an individual. C-reactive protein
(CRP) is an acute phase protein released from the liver (12) in response to IL-6 binding
the IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) activating mitogen-activated
protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3)
pathways (13). For nearly two-decades, circulating concentrations of CRP have been
used for CVD risk stratification (14, 15). The cytokine IL-6 is also used as a biomarker of
inflammatory health in cancer related cachexia and overall survival and quality of life in
patients suffering from gastrointestinal cancers (16, 17).
Over the course of the past few decades, research efforts have been focused on
identifying methods of controlling or optimizing the inflammatory response and chronic
systemic inflammation. Regular exercise has emerged as an effective, long-term
intervention. Aerobic and resistance exercise training programs lasting as little as 2 to 6months lowered circulating CRP, and reduced risk for CVD (18, 19). In addition, these
same types of exercise interventions are linked to improvements in the immune response
with physically active individuals releasing fewer pro-inflammatory cytokines like IL-6
and TNFα in response to LPS stimulation and reduction of the percentage of intermediate
monocytes (20, 21).
Recently, cannabis products have emerged as another potential modality for
controlling inflammation; however, exploration of the effects of cannabis on

3
inflammation are limited due to the schedule 1 status of Cannabis Sativa within the
United States (U.S.). Increasing localized medical and recreational availability of
cannabis products across the U.S. necessitates the need to study the true implications of
chronic cannabis use in health and inflammation. The active ingredients within cannabis
are known as phytocannabinoids. While there are greater than 100 identified
phytocannabinoids within Cannabis Sativa, delta-9-tetrahydrocannabidiol (THC) and
cannabidiol (CBD) have received the most attention. THC is known for its intoxicating
effects while CBD is sought after for its anti-inflammatory effects (22). The chemical
structure of CBD mimics that of endogenous cannabinoids (endo-cannabinoids)
anandamide (AEA) and 2-arachodonoylglycerol (2-AG) (23). Of the two primary
cannabinoid receptors 1 (CB1) and 2 (CB2), CBD is a partial ligand of CB2, which is
primarily expressed in immune cells, like monocytes, throughout the periphery (24-26).
Because CBD is unable to activate the CB1 receptor (27), which is heavily localized in
the central nervous system (CNS) (28, 29), it has few if any intoxicating effects.
Recent findings are fueling anecdotal accounts and advocation for use of cannabis
products not only in diseased populations, but as part of the daily routine of individuals
who are physically active (30). The majority of individuals claiming that the use of
cannabis in conjunction with exercise improves not only their enjoyment, but their
performance in that activity as well (30). While previous research does not support a link
between chronic use of cannabis and increased cardiorespiratory function during maximal
treadmill exercise in trained individuals (31), some individuals are under the impression
that the use of cannabis following exercise improves their recovery through the mediation
of inflammation (30). Chronic cannabis users that were physically active were at higher
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risk for CVD when compared to an equally physically active, non-user control group
based on circulating CRP (31); however, other studies suggest that recent cannabis users
were more likely to be below the population average CRP (32). In vitro, pre-treatment of
macrophages with a synthetic CB2 agonist at a 1 µM concentration resulted in a 25%
reduction in released IL-6 in response to LPS stimulation (33). Cannabis use has also
been linked to altered monocyte phenotype with decreased circulating CD16+ monocytes
in cannabis users (34). Isolated monocytes from cannabis users were also resistant to
interferon α (IFNα) induced CD16+ expression (34) and have altered migratory capacity
(35); However, whole blood LPS induced IL-6 release and monocyte phenotype have not
been assessed in physically active, chronic cannabis users.
Purpose
The purpose of this cross-sectional study was to assess monocyte phenotype in
physically active cannabis users (CU) and non-users (NU) and whether the LPS induced
release of IL-6 is different in the presence of CB2 agonists and antagonists in the whole
blood of CU and NU. Finally, this study sought to explore whether resting, circulating
concentrations of serum CRP and are different between CU and NU and related to
number of intermediate monocytes. The specific aims for this study were:
A1

Explore monocyte phenotype (classical, non-classical, intermediate) in
physically active CU and NU using cell surface expression of CD14 and
CD16.

A2

Assess resting concentrations of serum CRP and plasma IL-6 in physically
active CU and NU.

A3

Assess whole blood production of IL-6 in non-LPS-stimulated control
(control), LPS-stimulated control (LPS), pre-treatment with synthetic CB2
agonist (Ag) LPS-stimulated (Ag+LPS), and pre-treatment with synthetic
CB2 antagonist (Ant) LPS-stimulated (Ant+LPS) conditions.
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A4

Explore whether any relationships are present between cannabis use,
monocyte sub-populations (classical, non-classical, intermediate), resting
CRP and IL-6 concentrations and LPS stimulated IL-6 release.

The hypotheses for the outcomes of these specific aims were:
H1

There will be no difference in overall monocyte number between CU and
NU, but CU will have an increased number of intermediate monocytes
compared to NU.

H2

Resting concentrations of CRP and IL-6 will be elevated in CU compared
to NU.

H3

There will be no difference in IL-6 production in control, LPS, or
Ant+LPS conditions between CU and NU, but CU will produce
significantly more IL-6 than NU in the Ag+LPS condition.

H4

The number of intermediate monocytes will positively correlate with
resting CRP and IL-6 concentrations, and the number of intermediate
monocytes will positively correlate to measures of cannabis use. No other
relationships will be significant.
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CHAPTER II
REVIEW OF THE LITERATURE
Inflammation
Inflammation is initiated in response to trauma of tissue or invasion of a foreign
object, organism or pathogen. An inflammatory response is typically characterized by
local swelling, redness and heat due to increased blood flow to the site of injury or
infection (1). This acute response is intended to remove of the cause of the irritation and
promote remodeling and regeneration of the affected tissue. The localized effects of
inflammation can be attributed in part to proteins known as cytokines, which can mediate
both pro and anti-inflammatory actions (1). This acute inflammation, lasting less than a
couple of days, is highly beneficial and promotes removal of foreign pathogens and
damaged tissue while promoting growth and repair of local cells (1). However, chronic,
unresolved inflammation, lasting weeks to years, has been related to the progression and
development of chronic disease including: type 2 diabetes mellitus (2), cancer (3) and
cardiovascular disease (CVD) (4).
Monocytes
Monocytes are circulating leukocyte precursors to tissue macrophages and
dendritic cells and play a key role in initiation of the inflammatory response. Monocytes
can be further classified into three sub-categories known as classical, non-classical, and
intermediate based on their expression of CD14 and 16 (CD16) (36, 37). CD14 is a coreceptor which can act in tandem with toll-like receptor 4 (TLR4) as pattern recognition
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receptors for the bacterial endo-toxin LPS, which is the major component of the outer
membrane of Gram-negative bacteria (38-40). The CD14-TLR4 receptor complex can
bind LPS independently, but is accelerated in the presence of lipopolysaccharide binding
protein (LBP) (38). Activation of this receptor binding complex activates nuclear factor
kappa-light-chain-enhancer of activated B-cells (NF-κΒ) (8). Transcription of
inflammatory cytokine genes, including interleukin 6 (IL-6), interleukin 1 beta (IL-1ß)
and tumor necrosis factor-alpha (TNFα) are promoted by NF-κΒ activation (8, 9, 41, 42).
In addition, activation of this signaling pathway through LPS increases the expression of
TLR4 in a NF-κΒ dependent manner (43). The protein CD16, also known as fragment of
crystallization-gamma receptor-III (FcγRIII), functions as part of the adaptive immune
system by binding the Fc domain of immunoglobin g (IgG) antibodies (44) leading to
antigen presentation (45). Activation of the CD16 receptor on monocytes can also
promote monocyte mediated antibody-dependent cellular cytotoxicity and secretion of
pro-inflammatory cytokines like TNFα (46). With the combined functions of pathogen
recognition, cytokine secretion, antigen presentation, and cellular cytotoxicity, monocytes
are viewed as key integrators of the adaptive and innate immune response.
In healthy individuals, 85-95% of circulating monocytes exhibit relatively high
expression of CD14 on the cell surface, while the remaining 5-15% have relatively high
cell surface expression of CD16 (6, 7, 47). Classical monocytes are characterized by high
plasma membrane expression of CD14 and low expression of CD16, or CD14++/CD16(37) and are the most abundant sub-population representing 85-95% of all monocytes (6,
7). Compared to non-classical and intermediate monocytes, classical monocytes release
significantly more inflammatory cytokines in response to toll-like receptor (TLR)
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stimulation (6). Non-classical monocytes represent the second most abundant of the three
monocyte sub-types, typically consisting of 5-10% of the total monocyte population (6,
7). These cells exhibit relatively low expression of CD14 and high CD16 or
CD14+/CD16++ (37), and patrol vascular tissue for nucleic acids and viruses via TLR7
and TLR8 (48). Intermediate monocytes are the least abundant of the monocyte sub-types
(7) and express a phenotype of CD14++/CD16+ (37). These intermediate cells exhibit
moderate functions of both classical and non-classical sub-types (6, 10).
Elevated numbers of intermediate monocytes have been implicated in multiple
chronic diseases related to inflammation including: CVD (10, 11), rheumatoid arthritis
(49, 50) and type 1 diabetes mellitus (51). For example, macrophages and dendritic cells
can be found in atherosclerotic lesions, which, in turn, contribute to the inflammatory
microenvironment through production and release of cytokines and reactive oxygen
species (ROS) (52, 53). Inflamed vessels secrete monocyte chemokines C-C motif ligand
2 (CCL2), also known as monocyte chemoattractant protein 1 (MCP1) and C-C motif
ligand 5 (CCL5), promoting monocyte aggregation to the area followed by extravasation
of the monocyte into the tissue through rolling adhesion (54). Following extravasation,
these monocytes can differentiate into lipid rich foam cells that secrete ROS and
inflammatory cytokines contributing to plaque formation which can rupture leading to
stroke, thrombosis, or infarction (55, 56).
Cytokines
Immune cells secrete synthesized proteins known as cytokines, producing a
variety of effects ranging from promotion to suppression of inflammation. One such
multifaceted cytokine is (IL-6) which can be produced by muscle (57-59), fibroblasts (60,
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61), adipocytes (62, 63) and monocytes/macrophages (64-66). Due to the variety of
tissues that produce IL-6, this cytokine was initially identified as B-cell stimulatory factor
2 (BSF-2), hepatocyte stimulatory factor (HSF), and interferon beta 2 (IFN-ß2) until
1989, when it was realized they were all the same protein (67).
IL-6 and Exercise
Multiple studies have observed increased release of IL-6 following exercise (6871). IL-6 in the circulation is highest immediately following exercise (68-70) and IL-6
returns to normal resting concentrations within 24-hours following intense exercise (69,
71, 72). IL-6 can be secreted from multiple tissues including monocytes/macrophages as
a cytokine or skeletal muscle as a myokine. There are also observed increases of IL-6
mRNA in macrophages of regular exercisers compared to sedentary individuals following
acute aerobic exercise (73). However, it is still unclear what portion of secreted IL-6 in
response to sustained acute exercise is attributed to either immune or skeletal muscle
activities.
IL-6 secreted from skeletal muscle is referred to as a myokine, with increased
expression and release of IL-6 observed following exercise (58, 59, 74). The highest
observed concentrations of IL-6 in the circulation are observed immediately following
prolonged exercise (68-70). This increase in circulating IL-6 concentrations during and
following exercise is independent of muscle damage as well as concentrations of TNFα
(75) and often returns to normal concentrations within 24-hours following exercise (69,
71, 72). Others agree that IL-6 production is dependent on the availability of
carbohydrate within the muscle (76, 77). Additionally, IL-6 release following exercise
increases hepatic glycogenolysis and induces lipolysis (78). Skeletal muscle also
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increases C-C Motif Chemokine Ligand 2 (CCL2) expression following acute exercise
(71, 79). In CCL2 knockout mice, the migration of monocytes to muscle following acute
injury was impaired and expression of insulin-like growth factor (IGF-1) was dependent
on the presence of intramuscular macrophages (79). Increased intramuscular
macrophages have been observed following exercise in addition to increased mRNA
expression of CCL2 (71). Macrophages can be further classified into two sub types,
macrophage 1 (M1) and macrophage 2 (M2). In general, M1 macrophages are typically
activated by interferon gamma (IFNγ) or LPS initiating the immune response and release
proinflammatory cytokines (1). While M2 macrophages are associated with tissue repair
and wound healing through the release of anti-inflammatory cytokines (1). In humans, the
number of M2 macrophages has been found to positively correlate with muscle fiber
hypertrophy and numbers of muscle satellite cells following 12-weeks of cycle training
(80). Further, new research suggests that microRNA-155 and microRNA-21 are key
factors regulating macrophage activation and transition within skeletal muscle (81, 82).
Together, these findings suggest that skeletal muscle repair following acute injury, like
exercise, is dependent on recruitment of monocytes and regulation of M1 and M2
macrophages activity through myokines.
The stimulation of IL-6 production in monocytes occurs when pattern recognition
receptors (PRRs), like TLR-4, bind pathogen-associated molecular patterns (PAMPs) like
LPS (83). IL-6 can bind to both the soluble and membrane bound IL-6 receptor (IL-6R)
which allows for homodimerization of the IL-6/IL-6R complex with glycoprotein 130
(gp130) activating the mitogen-activated protein kinase (MAPK) and signal transducer
and activator of transcription 3 (STAT3) (13). Activation of these pathways leads to
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transcription of acute phase proteins like C-reactive protein (CRP) (84) primarily released
from the liver (12).
It is now theorized that the pro-inflammatory actions of IL-6 are attributed to the
activation of cells by the soluble IL-6/IL-6R complex binding to unbound gp130 on the
membrane of cells that do not express IL-6R. This action is also referred to as transsignaling, IL-6 trans-signaling is implicated in reducing neutrophil migration and
increasing monocyte recruitment and migration through down regulation of neutrophil
specific chemokines, and up regulation of monocyte chemokines like CCL2 and adhesion
molecules like vascular cell adhesion molecule (VCAM) (85-87). Conversely, the antiinflammatory effects of IL-6 are initiated when IL-6 binds to the IL-6R/gp130 complex,
which is expressed on the cell membrane. This action is also known as classic signaling
(88).
Much like the trend for the monocyte numbers mentioned above, some suggest
that elevations in skeletal muscle IL-6 following exercise are related to skeletal muscle
hypertrophy and recovery through the stimulation of skeletal muscle satellite cell
proliferation (89, 90). However, proliferation of satellite cells only occurred at low
concentrations (0.01-1 ng/ml) of IL-6 and not high concentrations (10-100 ng/ml) (90). In
fact, chronic, high skeletal muscle concentrations of IL-6 are implicated in muscle
atrophy and degradation (91).
Adipose tissue IL-6 gene expression varies based on adipose tissue location.
Subcutaneous adipose tissue has more IL-6 mRNA compared to visceral adipose tissue in
individuals with and without metabolic disease (92). It is estimated that 15-35% of
circulating IL-6 can be attributed to release from adipose tissue (93). However, much like
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in muscle, IL-6 released from adipose tissue is not dependent on damage to the tissue and
more linked to the metabolic state of the organism. Acute administration of IL-6 to
adipocytes in culture significantly reduces lipoprotein lipase activity, which has led
researchers to infer that increases in IL-6 in cancer patients may be responsible for loss of
body fat in some cancer related cachexia (94). In IL-6 knockout mice, administration of
intracerebroventricular IL-6 offset the occurrence of mature onset obesity when
compared to animals that did not receive IL-6 replacement therapy (95). These observed
effects might be attributed to injected IL-6 stimulated glucagon release and the resulting
increases in circulating blood glucose concentration (96). With evidence that adipose
secreted IL-6 may account for up to 35% of circulating IL-6 concentrations, it is possible
that accelerated adipose tissue accumulation may result in immune disruption and
increases in other circulating acute phase proteins such as CRP.
C-Reactive Protein (CRP)
C-reactive protein is a component of the innate immune system and plays a key
role in response to streptococcus pneumoniae (97). As previously discussed, this protein
is produced and released as part of the acute-phase response after induction by
proinflammatory cytokines like IL-6 (84). In addition, a positive correlation exists
between circulating CRP and body mass index (BMI), percent body fat and subcutaneous
abdominal fat (98). Furthermore, elevated circulating concentrations of CRP >1.0 mg/L
are implicated in increased risk for CVD and increased mortality in diabetic patients (15,
99).
Chronic exercise acts to decrease circulating CRP (19). Combined weight loss and
aerobic training over a six-month period resulted in a greater reduction of CRP than six
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months of weight loss alone (98). Conversely, when obese girls that underwent 12-weeks
of aerobic training, but did not experience significant reductions in total body weight or
body fat percentage, they did not experience significant reductions in CRP from pre to
post intervention (3.21 ± 2.48 vs. 2.73 ± 1.88 mg/L) (100). In comparing the effects of an
eight-week resistance training intervention between novice and experienced lifters, where
both groups participated in three training sessions per week, CRP was significantly lower
in both groups from pre to post intervention. However, experienced lifters demonstrated
greater reductions in CRP by an average of 54.5% compared to novice lifters with an
average reduction of 22.9% despite no overall changes in body mass or fat mass pre to
post intervention (101). Finally, a combined resistance and aerobic training model of
participants undergoing 24-weeks of training experienced significant reductions in CRP.
In these participants, there was no change in pre to post body weight or BMI, but body fat
percentage decreased from pre to post intervention (102). Together, these study findings
suggest that reductions in CRP are not solely reliant on exercise but involve changes in
body composition as well.
Chronic Exercise and
Immune Function
Immune dysfunction can promote a chronic inflammatory state. Repeated bouts of
moderate exercise reduce systemic inflammation (103, 104) and reduce susceptibility to
disease (105), which may be attributable to alterations in immune function. Physical
inactivity has been related to accumulation of visceral fat mass, increased risk for
diabetes, CVD, cancer, and depression, and a chronic low-grade inflammatory state (106,
107). The American College of Sports Medicine (ACSM) is using the phrase, “Exercise
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is Medicine” in an effort to encourage the use of exercise to mediate help control
inflammation and prevent disease risk (106, 108, 109).
Assessment of monocyte phenotype and immune function via LPS stimulation has
been performed in individuals that were either physically active or physically inactive.
Physically inactive individuals underwent a 12-week combined resistance and aerobic
training program three times a week. From pre to post exercise training, physically
inactive individuals experienced significant increases in strength and V̇O2 max, with post
intervention values similar to those of the physically active group. LPS stimulated
production of TNFα in whole blood samples was significantly lower from pre to post in
physically inactive individuals suggesting that training decreased the pro-inflammatory
immune response. This effect could be attributed to the reduction from pre to post of the
total percentage or intermediate monocytes in these physically active individuals (21).
Similar effects were observed in comparison of LPS stimulated release of IL-6 in
physically active females compared to non-physically active females, with significantly
lower stimulated IL-6 in physically active individuals. However, unlike the previously
described study, there were no observed difference in stimulated TNFα production or
monocyte sub-populations between activity groups (110). These results suggest that
changes in TNFα secretion may be dependent on changes in monocyte phenotype,
specifically changes in the percentage of intermediate monocytes.
Conversely, excessive exercise training, also known as over training, is implicated
in decreased performance and immune suppression (111, 112). Three weeks of repeated
intense exercise bouts reduced CCL2 after the training period and remained suppressed
following four weeks of recovery (113). In fact, this phenomenon is further explained by
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the J-Shaped Curve, which is used to describe risk of upper respiratory tract infection
depending on physical activity status. In this model, sedentary individuals are at higher
risk for illness compared to those engaging in regular, moderate exercise, and individuals
that are engaging in excessive exercise without adequate recovery at higher risk for
illness than the other two groups (114).
Monocyte Phenotype and
Activity Following
Acute Exercise
Acute, maximal exercise elicits a proinflammatory response and phenotypic shift
in monocyte populations (115). Following a maximal progressive exercise test on a
treadmill, with exercise testing lasting 13.3 ± 2.8 minutes, circulating classical monocytes
decreased ~8% from pre-exercise while intermediate and non-classical monocytes
increased by 16% and 48% pre to post-exercise, respectively. Other studies reported
increased CD16+ monocytes in the circulation following intense exercise (116-118), and
is believed to be linked to increased shear stress on the vascular endothelium with
exercise and mobilization from the splenic reserve (119, 120). Expression of TLR4 pre to
post exercise is also significantly lower, with classical and intermediate monocytes
experiencing greater reductions than non-classical monocytes. Generalized monocyte
expression of CD14 is also significantly lower pre to post exercise and is significantly
lower across all three monocyte sub-sets. Exercise induced significantly greater
expression of CD16 on intermediate monocytes pre to post exercise but was unaltered on
non-classical monocytes. LPS induced IL-6 and IL-10 secretion was significantly lower
from pre to post exercise while TNFα release was significantly greater following
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exercise. Further, the ratio of IL-6 to IL-10 LPS stimulated release was significantly
greater following maximal exercise (115).
Cannabis and Cannabinoids
Cannabis products derived from the seeds, leaves, and flowers are often subdivided by their cultivar, or strain, including Cannabis Indica, Cannabis Sativa,
Sativa/Indica Hybrids and Hemp (121). Anecdotal accounts suggest varying perceived
effects that are dependent on strain of use, with users of Cannabis Indica reporting
cannabis use for pain management and sedation, while users of Cannabis Sativa reporting
cannabis use for its effects on euphoria and energy enhancing qualities (122). However,
new research has failed to uphold these common beliefs. Genetic analysis of over 30strains marketed as either Cannabis Sativa, Cannabis Indica or Hybrid obtained from
recreational dispensaries showed there was no genetic evidence supporting the distinction
of these three strains. In addition, recent research from the University of Northern
Colorado suggests strong genetic variability within identically named products like
“Purple Kush”, “Blue Dream” and “Girl Scout Cookies” (123). Today, the current
consensus is there are two distinct categories of cannabis-based genetics, Cannabis Sativa
and hemp. Current research on both the genetic analysis of strains and developing a basic
physiological understanding of the effects of cannabis is restricted; limited not only
within the United States (U.S.), but around the world. Research within the U.S. is
regulated by the Drug Enforcement Agency (DEA). Until 2016, researchers were
required to utilize the raw cannabis flower supplied cannabis from the University of
Mississippi. However, genetic analysis of research grade cannabis obtained from the
University of Mississippi revealed that it was more genetically similar to hemp than
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Cannabis Sativa (124). These new findings have implications that even studies using
DEA supplied cannabis for research may not be applicable to recreational or medical
grade cannabis.
According to a report by the National Institute on Drug Abuse (NIDA), 9% of
adults within the United States have used cannabis products within the past month (125).
Within the past decade, there has been increased enthusiasm for the medicinal and
recreation legalization of cannabis products. This change is largely due to the
psychoactive and medicinal properties of compounds, also known as phytocannabinoids,
which are found within the Cannabis Sativa plant. There are more than 100 identified
phytocannabinoids within cannabis (126), yet two of these cannabinoids delta-9tetrahydrocannabidiol (THC) and cannabidiol (CBD) have received the majority of the
attention from researchers and the general population alike. However, THC and CBD are
not naturally found in large quantities within cannabis. Instead, THC and CBD are
secondary products of the precursor’s delta-9-tetrahydrocannabinolic acid A (THCA-A)
and cannabidiolic acid (CBDA), respectively and can only be produced when
decarboxylated through heat (127).
Active THC and CBD produce effects throughout the body through activation and
utilization of the body’s endocannabinoid system. The body’s primary endogenous
cannabinoids are anandamide (AEA) and 2-arachodonoylglycerol (2-AG) and bind to
cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors expressed in specific tissues
throughout the body (128). AEA is the primary endocannabinoid ligand of CB1, while 2AG is the endogenous ligand for CB2 (128). Within the central nervous system (CNS),
endocannabinoids are used as retrograde signaling molecules released from the post-

18
synaptic membrane to inhibit further neurotransmitter release through activation of
cannabinoid receptors on the pre-synaptic terminal (129-131). CB1 and CB2 receptors
share 48% amino acid sequence identity (132). Both CB1 and CB2 are trimeric, Gprotein coupled receptors (133). The α sub-unit of the G-protein coupled to the receptor
has demonstrated suppressive effects on cyclic adenosine monophosphate (cAMP)
production through inhibitory actions on adenylyl cyclase (AC) (134) whose actions were
blocked with pertussis toxin, a known inhibitor of the α sub-unit (135).
The CB1 receptor is heavily expressed in neural tissue of the CNS and to a lesser
extent in the periphery (28, 29). Conversely, while the CB2 receptor has been observed to
be expressed by cells in the CNS, like microglial cells (136), it is more abundantly
expressed throughout the periphery (137, 138), especially in immune tissues like
monocytes and macrophages (24-26). THC binds and activates both CB1 and CB2
receptors (27, 139) while the observed actions of CBD are acting as a CB2 agonist and
antagonize CB1 receptor activation (27). The elevated receptor localization of CB1
within the CNS and its high affinity for THC have implicated THC as the main
intoxicating ingredient in cannabis. On the other hand, CBD is viewed as a nonintoxicating compound.
Cannabis Use and Health
Phytocannabinoids like THC and CBD are highly lipophilic, and repeated
subcutaneous injection of THC for 26-days causes an accumulation of THC and its
metabolites 11-hydroxytetrahydrocannabinol and 8, 11-dihdroxytetrahydrocannabinol are
ten times more likely to accumulate in adipose tissue compared to any other tissue;
however, concentrations of all three compounds gradually dissipated following 2-weeks
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of discontinued use (140). Furthermore, no differences in total body fat, or hepatic fat
were present when cannabis users were compared with non-users; however, abdominal
visceral fat was significantly greater in cannabis users when compared to age and body
mass index (BMI) matched control participants (141).
There is limited research available as it pertains to the chronic effect of cannabis
use on resting heart rate in physically active individuals when not under the acute
influence of cannabis. Previously, cross-sectional research in our laboratory observing
physically active males and females determined that there was no difference in resting
heart rate when at least 12-hours removed from last cannabis use when comparing
cannabis users to non-users (31). There have been mixed findings on the acute effects of
cannabis use on resting systolic and diastolic blood pressure. There were no reported
changes in systolic blood pressure (142-144) and one study reported a slight decrease in
diastolic blood pressure (142) with no reported change in others (143, 144). Interestingly,
when physical activity status is consistent in both cannabis and non-cannabis using
groups, there are no observed differences in either male or females between users and
non-users (31).
Acute use of cannabis exerts a bronchodilator effect on pulmonary tissue as
measured by improvements in forced vital capacity (145-149). In our lab, male,
physically active cannabis users exhibited no difference, when compared to non-cannabis
using individuals, in pulmonary function as measured by forced expiratory volume in one
second when at least 12-hours removed from last use (31). Recent, unpublished findings
from our laboratory indicate that chronic cannabis use is not associated with impaired
respiratory function in physically active females.
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In terms of overall metabolic health, cannabis users had greater carbohydrate
intake and HDL concentrations compared to non-users, but no differences in overall
caloric intake, fasting glucose, LDL or free fatty acid concentrations. Cannabis users also
demonstrated decreased adipocyte insulin resistance index and no overall dysfunction in
ß-cell function or insulin sensitivity in response to an oral glucose tolerance test (141).
Together, these results suggest that both acute and chronic cannabis use may affect
overall health through altered body composition and cardiovascular, pulmonary and
metabolic health, but more investigation is necessary.
Cannabis and Exercise
Exercise is a multifaceted stressor that requires integration and coordination of
multiple systems throughout the body including cardiovascular, respiratory, and skeletal
muscle systems that are heavily dependent on mode of exercise (i.e., endurance, strength,
power). Acute cannabis use is associated with elevated resting heart rate following both
inhalation and oral ingestion (142, 144, 150-152). When physical activity is considered,
acute use of cannabis elevates resting heart rate, which persists throughout sub-maximal
exercise and recovery duration when compared to control and inhaled placebo conditions
(153), with similar observations in maximal exercise up to 80% of maximal work
capacity (154). These effects may be in part due to the presence of CB1 receptors on
vagal efferent and afferent neurons (155, 156), which could alter the vagal tone
innervating cardiac tissue.
With respect to endurance exercise, early studies suggest that acute administration
of THC decreases peak work capacity, maximal workload, and exercise duration on a
bike (154, 157, 158). Moderate intensity exercise lasting 35-45 minutes on a bike has also
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been observed to illicit release of THC from adipose tissue increasing circulating THC
from pre to post exercise (159, 160). However, neither of these studies reported if the
observed increases in circulating THC post exercise were associated with a psychoactive
effect in participants (159, 160). Very few studies have followed up on the potential
physiological and psychological implications of this response. Acute administration of
cannabis prior to maximal exercise does not appear to induce any significant changes in
V̇O2 or V̇CO2 (154). A recent study in our laboratory supports these earlier findings. In a
cross-sectional study of male, chronic users compared to non-users, there was no
difference in relative V̇O2 max or perceived exertion at termination of exercise during a
progressive treadmill assessment when users were at least 12-hours removed from last
use (31). The observed lack of difference in relative V̇O2max among physically active
male cannabis users and non-users appears to be consistent in physically active females
as well (data unpublished).
Skeletal muscle expresses both CB1 and CB2 receptors (161), which suggests that
the acute and chronic use of cannabis have the potential to alter skeletal muscle
physiology and function. Interestingly, muscular strength as evaluated by grip strength
was not different between acute cannabis or acute placebo use conditions (157). A recent
cross-sectional study from our laboratory sought to build off of these findings and
assessed physically active male cannabis users and non-users for grip strength and lower
limb force production, finding no differences between groups (31). More recent
mechanistic studies have also explored muscle function. In an ex vivo model using mouse
muscle fibers, stimulation with cannabinoids increased muscle fatigue, but did not alter
peak contractile amplitude (162). In addition, cannabinoid treatment decreases the
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calcium sensitivity of the contractile proteins, as well as decreases release of Ca 2+ from
the sarcoplasmic reticulum and reduces uptake of Ca2+ of the sarcoplasmic reticulum
ATPase (162).
Cannabinoids and Immune Function
Although a number of other components within cannabis are currently being
explored, the cannabinoid CBD is quickly gaining popularity for its proposed antiinflammatory actions in diseased populations (163). Even physically active individuals
are now using cannabis as part of their exercise routines in an effort to help mediate
exercise associated inflammation and pain (30). However, current research on the effects
of acute and chronic use of cannabis on immune health and function is limited, especially
in human models. Lung associated macrophages were significantly greater in mice
exposed to cannabis smoke twice daily for 40-minutes a session at 1, 2, 3, and 4-months
following initial exposure. Lung epithelial damage was significantly greater in mice at 2,
3 and 4-months after cannabis exposure, with overall increased inflammatory cell
(macrophage, lymphocytes, and granulocytes) infiltration at 1, 2, 3, and 4-months after
exposure compared to control animals (164). This suggests that even four months of
chronic cannabis exposure increases inflammatory cell migration into the lungs in
response to cannabis associated tissue damage.
Cannabis, Cannabinoids
and Monocytes
While chronic cannabis use promotes immune cell migration and tissue damage in
animal models, the potential medicinal effects of cannabis use in a diseased population is
unclear. In a cross-sectional study assessing number of inflammatory CD16+ monocytes
in individuals diagnosed with human immunodeficiency virus (HIV) using or not using
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cannabis products, HIV cannabis users had significantly lower numbers of circulating
CD16+ monocytes compared to HIV infected non-users. Further, there was no significant
difference in CD16+ monocytes between HIV cannabis users and healthy, non-HIV
infected non-users. Although other mechanisms are currently being investigated,
Interferon-γ inducible protein 10, which is another proinflammatory protein released
from monocytes that has been implicated in promotion of HIV related
neuroinflammation, was significantly lower in cannabis users with HIV infection
compared to non-users. Additionally, when monocytes harvested from HIV infected
cannabis users were treated with interferon α (IFNα), the cells were unresponsive to
inducible expression of CD16+, whereas HIV infected non-users and non-infected healthy
controls did express CD16 in response to IFNα. This action was further supported when
IFNα induced CD16+ was blunted with pre-treatment of THC (34). In another study
assessing cannabinoids and immune related neurotoxicity, cultured THP-1 cells, a model
for human monocytes, stimulated neurotoxicity was significantly reduced in cell culture
supernatant when pre-treated with the synthetic CB2 ligand JWH-015. This effect was
blocked when the cells were treated with the CB2 antagonist SR144528 prior to
stimulation with JWH-015 (136). Early indications implicate that chronic use of cannabis
may be detrimental in an apparently healthy population; however, results from clinical
populations could prove to be beneficial in the future.
As of late, researchers are assessing how the chronic use of cannabis affects
monocytes in the apparently healthy, general population. In human isolated monocytes,
migratory capacity and CB1 and CB2 receptor mRNA expression were measured in
cannabis users and non-users. In cannabis users, isolated CD14+ monocytes had
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significantly reduced migratory capacity in culture compared to isolated monocytes from
non-users in response to treatment with CCL2 and isolated serum. When cells were pretreated with cannabinoids THC and CBD monocytes from non-users, there was no
change in migratory capacity compared to basal conditions when stimulated with CCL2.
However, cannabis users demonstrated >25% reduction from basal migratory capacity
when pre-treated with THC and CBD in response to CCL2. This suggests that chronic
cannabis use in apparently healthy individuals could impair the ability of monocytes to
migrate into affected tissue. Further, cannabis user monocytes had four times greater
mRNA expression of CB1 compared to non-users. There was no significant difference
between cannabis user and non-user expression of CB2 mRNA (165). These results
imply that chronic cannabis users may be more sensitive to the effects of CB1 ligands
like THC in cannabis products. Another study has reported a similar effect in patients
suffering from multiple sclerosis (MS). When both healthy cannabis users and cannabis
users with MS monocytes were stimulated with CCL2, stimulated monocyte migration
was reduced by 50%, when compared to healthy, non-user controls and non-users with
MS. There were no significant differences in circulating concentrations of CCL2 between
any groups (166). Together, these results suggest that the chronic use of cannabis in both
healthy and clinical populations significantly impairs circulating monocytes’ ability to
migrate into affected tissue.
Cannabinoids and Cytokines
While the migratory capacity of monocytes in clinical and healthy populations is
just beginning to be explored, there is currently limited information available on how
cannabis affects production and release of inflammatory cytokines. In BV-2 microglial
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cells, a cell model for CNS macrophages, pre-treatment with varying concentrations of
THC (1, 5, 10 µM) and CBD (1, 5, 10 µM) prior to LPS stimulation resulted in dose
dependent decreases of IL-1ß and IL-6 when measured in culture supernatant. There was
no significant difference in THC or CBD induced suppression of IL-1ß at 1, 5 or 10 µM
concentrations of either cannabinoid; however, while LPS induced release of IL-6 was
significantly lower (~25% reduction) at 5 and 10 µM THC, treatment with 1 µM CBD
induced similar reductions in IL-6 release compared to 5 and 10 µM THC. The effect of
CBD was further exaggerated at 5 and 10 µM treatment with respective reductions of
85% and 91%. Further, treatment with 10 µM THC and 10 µM CBD inhibited release of
interferon (IFN) ß, and significantly reduced the LPS induced increase of IL-1ß and IFNß
mRNA expression within stimulated cells. When assessing what intracellular signaling
pathways were associated with these results, treatment with CBD but not THC decreased
activity of the proinflammatory NF-κΒ pathway with observed increases in CBD induced
phosphorylation of STAT3, 2 and 4 hours post LPS stimulation (167). This means that
the acute administration of a CB2 agonist, like CBD, prior to immune challenge,
produces a dose dependent suppression of pro-inflammatory cytokine release through
inhibition of the NF-κΒ signaling pathway.
While the current available research has described the acute administration of
cannabinoids like CBD and THC to have suppressive effects on inflammation, the
associated release of cytokines from immune cells also play a key role in cell-to-cell
communication. In cannabis users and non-users that were either healthy or had MS, IL17 was significantly lower in both cannabis user groups compared to non-user groups. IL17 is a key pro-inflammatory cytokine released from T-helper 17 (Th17) cells that
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initiates productions of inflammatory factors like TNFα, IL-6 and MCP-1 (1). In addition,
total T-helper cell 1 (Th1) cytokines in resting plasma samples (IFNγ, IL-2 and TNFα)
was significantly lower in both cannabis groups. A similar effect on T-helper cell 2
cytokine concentrations was also reported with cannabis users demonstrating
significantly lower resting plasma concentrations of IL-4, IL-10, and IL-13 (166). In mice
exposed to cannabis smoke for 40-minutes per session two times per day for 2-months,
lung homogenate IL-6 was significantly elevated compared to controls, as were lung
homogenate concentrations of IL-10, MCP-1, IFNγ, TNFα, and IL-12. Further
exploration of lung homogenate concentrations of inflammatory cytokines found that
cannabis-using mice had increased concentrations of IL-10, MCP-1, IFNγ, TNFα and IL12 compared to tobacco using mice that were using for the same duration. However, there
were no differences in cannabis or tobacco using mice concentrations of IL-6 (164).
Consequently, it is unclear if the reductions in release of inflammatory cytokines like IL6 and TNFα is a result of CB receptor mediated decreased activation of NF- κΒ in
monocytes, or the result of suppression of cytokines from other immune cells.
In cannabis users diagnosed with cannabis use disorder, using cannabis on
average of 56.67 ± 7.23 months, resting concentrations of serum cytokine concentrations
(IL-1ß, IL-6, IL-8, IL-12p70, IFNγ, and TNFα) were evaluated and compared to a control
group that had never used cannabis. There was no difference in resting concentrations of
IL-12p70 or IFNγ between cannabis users and non-users. Concentrations of IL-6, IL-1ß,
IL-8, and TNFα were significantly higher in cannabis users compared to non-users. This
suggests that the chronic use of cannabis in individuals with cannabis use disorder may
cause immune disruption and create a pro-inflammatory environment. However, physical
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activity status, recent exercise, and acute use of cannabis were not taken into account in
this study, which could have significantly altered many of these biomarkers (168). New
data from our laboratory found that there are no significant differences between resting
serum IL-6 in physically active cannabis users (1.28 ± 0.49 pg/mL) and non-users (1.28 ±
0.74 pg/mL), where users used an average of 4.5 times a week with an average duration
of use of 6 years. Results from our laboratory showed that our observed resting
concentrations of IL-6 were significantly lower than non-user control (12.15 ± 3.48
pg/ml) and cannabis user (17.75 ± 5.17 pg/ml) groups (168). This suggests that exercise
may have protective effects over the possible immune disruption observed with chronic
cannabis use. Contrary to the previously discussed findings on cannabis use promoting
increases in pro-inflammatory cytokines like TNFα and IL-1ß, a more recent study has
described a significant negative relationship between the number of cannabis using days
and IL-1ß concentration in individuals using cannabis and alcohol (169). These findings
suggest that cannabis use may increase resting concentrations of pro-inflammatory
cytokines; however, exercise may attenuate this effect. Cannabis use may also decrease
alcohol consumption associated increases in pro-inflammatory cytokines like IL-1ß.
Cannabis and C-Reactive
Protein
There have been mixed findings on cannabis use and circulating CRP. In
individuals with Crohn’s Disease, 8-weeks of a cannabis smoking intervention did not
cause any significant changes in circulating CRP (170). However, recent cannabis users
were more likely to be below the population mean for CRP, suggesting that cannabis use
may have acute anti-inflammatory effects (171). In physically active males, our
laboratory observed no difference in resting CRP concentrations between cannabis users
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and non-users, but based on average group concentrations, cannabis users (1.76 ± 2.81
mg/L) were at moderate risk for CVD compared to non-users (0.86 ± 1.49 mg/L) who
were at low risk for cardiovascular disease (31). Preliminary, unpublished data from our
laboratory show a similar effect in females with cannabis users (1.47 ± 2.50 mg/L) again
at higher risk for CVD compared to non-users (0.50 ± 0.39 mg/L) based on CRP.
Consequently, it is possible that the phytocannabinoids in cannabis could alter immune
and monocyte function leading to this increased risk for CVD. Exploration into the
potential mechanisms of CRP dysregulation in cannabis users is warranted to discern if
these findings are the result of changes in monocyte phenotype or another mechanism.
Conclusions
Sustained, moderate exercise programs have been shown to improve immune
function and reduce risk for cardiovascular disease in aerobic, resistance, and combined
training models. Recent findings suggest that some physically active individuals are now
regularly using cannabis in combination with their exercise as a potential means to
improve recovery from exercise. Research has demonstrated that acute and chronic
cannabis use suppresses monocyte and immune cell migration and decreases cytokine
release. While there are new implications that the chronic use of cannabis increases rick
for CVD, as defined by circulating concentrations of CRP, in physically active cannabis
users; the mechanism for this observation is still unclear. It is possible that the chronic
use of cannabis alters monocyte phenotype and whole blood immune function leading to
this increased risk. No study to date has assessed monocyte phenotype or the LPS
induced immune response in physically active cannabis users.
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CHAPTER III
METHODOLOGY
Participants
Study participants were recruited from the surrounding area of the University of
Northern Colorado through fliers, social media, and word of mouth. A total of N=23 male
and female participants (n=12 cannabis users [CU], n=8 males; n=12 non-users [NU],
n=8 males) were recruited and underwent health related measurements and blood
collection over the course of three study visits as outlined in Figure 3.1. Study
participants had to be between the ages of 18 and 40 years, apparently healthy, engaging
in at least 150-minutes of moderate activity per week, and use cannabis products at least
5-times per week for the past 6-months (CU), or not have used any cannabis products
within the past 6-months (NU). Participants were not currently using tobacco products,
pregnant, or did not have a musculoskeletal or neurological injury. This study was
approved by the Institutional Review Board (IRB) at the University of Northern Colorado
(Appendix A).
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Figure 3.1. Study Layout and Progression. PARQ=Physical activity readiness
questionnaire, IPAQ=International physical activity questionnaire, DFAQ-CU=Daily
sessions, frequency, age of onset, and quantity of cannabis use questionnaire, BDIII=Beck Depression Inventory-II, V̇O2max=Maximal volume of oxygen consumption.
Visit 1: Informed Consent and Surveys
When participants arrived at the exercise physiology laboratory (room 1610) in
Gunter Hall, they were provided with the institutional approved informed consent and
allowed adequate time to review the document. After obtaining informed consent and
addressing any questions or concerns, participants were assigned a random participant
number. Participants then completed Medical History and the Physical Activity
Readiness Questionnaire (PAR-Q) forms. The International Physical Activity
Questionnaire–Short Format (IPAQ) was then given to assess participant physical activity
habits over the past seven days (172). For quantification of cannabis use, participants
completed the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use
questionnaire (DFAQ-CU) (173). The Beck Depression Inventory-II (BDI-II) was
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administered to assess participants depressive score and rating (174). Participants were
excluded from partaking further in the study if they failed to meet the previously
mentioned requirements.
Visit 2: Hydration, Anthropometric Measures
and V̇O2max Assessment
Prior to visit 2, participants were asked to refrain from vigorous physical activity
for at least 48-hours, and abstain from alcohol, caffeine, cannabis and any nonprescription drug use for at least 12-hours prior to the visit.
Hydration Analysis
Prior to exercise testing, participants provided a urine sample in a urine collection
container (Dynarex, Orangeburg, NY), and urine specific gravity was analyzed with a
PAL-10S-4410 refractometer (ATAGO, Tokyo, Japan). Participants with a urine specific
gravity greater than 1.025 were considered dehydrated and were asked to return to the lab
at a later time when they were adequately hydrated.
Anthropometric Measures: Height,
Weight, Waist to Hip Ratio and
Body Fat Percent
Height was assessed without shoes using a wall-mounted stadiometer (Secca
Precision for Health, Hamburg, Germany). Participant body mass was assessed using a
digital platform scale (Detecto, Webb City, MO) without shoes, bulky clothing, and
emptied pockets. Waist to hip ratio was taken by measuring the circumference of the
waist, defined as the narrowest point between the umbilicus and xyphoid process, and the
hips, defined as the widest point below the umbilicus using a Gulick measurement tape
(Fabrication Enterprises Inc., White Plains, NY). Body fat percentage was assessed using
a standard 7-site skinfold assessment (pectoral, triceps, sub-scapular, mid-axillary,
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abdominal, suprailliac, and thigh). A spring-loaded Lange Skinfold Caliper (Cambridge
Scientific Industries, Inc., Cambridge, MA, USA) was used to obtain measures of each
site, in sequential order, for a total of two times. If the first two measurements differed by
more than 2mm, a third measure was taken at that specific site. The average fold
thickness for each site was used to calculate body density and body fat percentage using
equations from Harrison et. al. 1988 (175)
V̇O2max Assessment
Prior to the exercise assessment, participants were fitted with a Polar heart rate
monitor (Polar Electro Inc., Bethpage, NY, USA) and asked to sit quietly for 5-minutes.
Following the 5-minutes of rest, resting heart rate and blood pressure (American
Diagnostic Corporation, Hauppaugge, NY) were obtained. Maximal oxygen consumption
(V̇O2max) was assessed using the Bruce Ramp Protocol (176) and a TrueOne 2400
Metabolic Measurement System (Parvomedics, Model: MMS-2400; Sandy, UT, USA).
This graded protocol had participants walk/jog as the speed and incline of the treadmill
(Trackmaster, Model: TMX425CP, Full Vision Inc., Newton, KS, USA) was increased
every 3-minutes until the participant reached volitional fatigue. The detailed protocol
with treadmill speed and grade is presented in Table 3.1. In the final 30-seconds of each
stage and immediately upon the termination of exercise, rate of perceived exertion (RPE)
was obtained using the 0-10 Modified Borg Scale (177). For a Bruce assessment to be
considered a true V̇O2max any two of the four following criteria needed to be met: 1.) A
plateau in V̇O2 despite an increase in workload, 2.) Heart rate within 10 bpm of age
predicted heart rate max calculated by: 220-participant age, 3.) A respiratory exchange
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ratio greater than 1.10, and 4.) A self-reported RPE greater than 8.5 on the Modified Borg
Scale immediately after termination of exercise.
Table 3.1: Bruce Protocol
Stage

Treadmill Speed
Treadmill Grade (%)
(mph)
Warm-up
1.7
0
Stage 1
1.7
10
Stage 2
2.5
12
Stage 3
3.4
14
Stage 4
4.2
16
Stage 5
5.0
18
Stage 6
5.5
20
Stage 7
6.0
22
Stage 8
6.5
24
Note: Stages are 3-minutes long and each successive stage starts immediately following
the previous stage
Visit 3: Blood Sample Collection, Flow Cytometry
and Immune Stimulation
Blood Sample Collection
Blood draws took place in the Exercise Physiology Laboratory in Gunter Hall in
the morning between the hours of 5-9 am at least 7-days following visit 2 to allow for
adequate participant recovery. Participants were asked to arrive to the laboratory 12hours fasted (except water ad libitum), at least 72-hours removed from their last bout of
vigorous physical activity, and 12-hours removed from last use of alcohol, caffeine,
cannabis or any other non-prescription drug use. A trained phlebotomist collected a 40
mL blood sample via venipuncture. A total of 10 mL of blood was collected in serum
separation tubes (SST) (Thermo Fisher Scientific, Waltham, MA) and allowed to clot for
15-minutes at room temperature. The SST sample was then centrifuged at 800 rcf for 10minutes (Model: Marathon 21K, Thermo Fisher Scientific, Waltham, MA). The
remaining 30 mL of blood was collected in EDTA treated vacutainers (Becton Dickinson,
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Franklin Lakes, NJ). EDTA treated blood was then aliquoted for whole blood, plasma,
immune stimulation and flow cytometry analysis. Plasma was obtained by centrifuging
the EDTA vacutainer for 10-minutes at 800 rcf. Whole blood for immune stimulations
and flow cytometry was kept on ice for later analysis. Aliquoted samples of whole blood,
plasma and serum were stored at -80°C for biomarker analysis.
Flow Cytometry Monocyte
Phenotype
Whole blood collected in EDTA treated vacutainers was prepared for analysis of
monocyte number and phenotype using flow cytometry. Whole blood, 150 µL, was
stained for CD14 (anti-human CD14-FITC) and CD16 (anti-human CD16-PE/CY7)
(eBioscince, San Diego, CA) following lysis of red blood cells with 1X red blood cell
lysis buffer (BioLegend, San Diego CA) and blocking of Fc receptors with Fc-Blocker
(eBioscience, San Diego, CA). Auto-fluorescent and anti-mouse IgG1 FITC and PE/CY7
isotype controls were also prepared for proper gating analysis (eBioscience, San Diego,
CA). Prepared samples were run on an Attune NxT flow cytometer (Thermo Fisher
Scientific, Waltham, MA), stimulated with a 488 nm laser and detected in the FITC and
PE/CY7 channels. Data were analyzed in FCS Express 6 (De Novo Software, Glendale,
CA), setting gates for the monocyte sub-population, doublet exclusion and monocyte coexpression of CD14 and CD16 for CD14++CD16-, CD14++CD16+, and CD14+CD16+
monocyte populations (Figure 3.2).
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Figure 3.2. Flow Cytometry Monocyte Gating Strategy. Data were analyzed in FCS
Express (De Novo Software, Glendale, CA). A. Data points were graphed using forward
scatter area (FSC-A) and forward scatter height (FSC-H). Gate G1 was placed around all
singly suspended cells, excluding for: doublets, dead cells, and any remaining red blood
cells or particulate. B. Gate G2 was placed over the specific monocyte cell population. C.
Cells from G2 were graphed based on expression of CD14 (x-axis) and CD16 (y-axis).
Cells in gate G3 were excluded for low expression of both CD14 and CD16. Quadrant
positioning was determined by FITC and PE-CY7 isotype controls for CD14 and CD16
respectively. D. Cells in the upper left quadrant were classified as non-classical
monocytes, the upper right quadrant cells were classified as intermediate monocytes, and
lower right quadrant cells were categorized as classical monocytes.
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Whole Blood LPS Immune
Stimulation
Whole blood inflammatory response was measured after preparing EDTA treated
whole blood at a 1:10 dilution with prepared sterile Rowell Park Memorial Institute
(RPMI) cell culture media. Prepared RPMI consisted of sterile RPMI (Sigma Aldrich, St.
Louis, MO) treated with L-glutamine, streptomycin and penicillin (Sigma Aldrich, St.
Louis, MO) at a 1:100 dilution. For each treatment condition, control, LPS, Ag+LPS and
Ant+LPS, 2 mL of prepared blood was aliquoted into 24-well plates. The Ant+LPS wells
were treated with 10 µL of a 200 µg/mL SR144528, a synthetic CB2 antagonist (178),
stock solution for a final concentration of 1µg/mL in the well and incubated for 1-hour at
37°C and 5% CO2. The Ag+LPS and Ant+LPS wells were then treated with 10 µl of a
200 µg/mL JWH-015, a synthetic CB2 agonist (179), stock solution for a final
concentration of 1 µg/mL and incubated for 1-hour 37°C and 5% CO2. The LPS,
Ag+LPS and Ant+LPS wells were then treated with 50 µL of 1 mg/mL prepared LPS (S.
enteriditis; Sigma Aldrich, St. Louis, MO) for a final concentration of 25 µg/mL of LPS.
Samples incubated for 24-hours at 37°C and 5% CO2 were then centrifuged at 800 rcf for
10-minutes at 4°C. Cell culture supernatant was harvested, aliquoted and stored at -80°C
for analysis of inflammatory proteins.
Protein Quantification
Stimulated cell culture supernatants were analyzed for protein concentration of
IL-6 using an enzyme linked immunosorbent assay (ELISA) (RayBiotech, Norcross,
GA). The inter-assay coefficient of variability (CV) for LPS stimulated IL-6 supernatants
was <10% and intra-assay CV was <6%. Isolated serum was analyzed for CRP using an
ELISA (ALPCO Diagnotics, Salem, NH). Resting concentrations of IL-6 were assessed
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using isolated plasma and a high sensitivity ELISA (Abcam, Cambridge, MA). Analysis
for resting concentrations of CRP and IL-6 was done using a single plate and had intraassay CV’s of <6%. All samples and ELISA kits were prepared according to manufacture
specifications and analyzed using an ELx800 BioTek microplate reader (BioTek
Instruments, Winooski, VT) at the recommended wavelength of 450 nm.
Statistical Analysis
All data were analyzed using SPSS (V. 24; IBM Analytics, Armonk, NY)
assessed for normalcy, distribution of variance and log transformed as necessary. A
standard unpaired t-test was used to compare descriptive measures, resting concentration
of CRP and IL-6, and monocyte populations between CU and NU groups. Differences
between males and females were assessed for all descriptive variables using an unpaired
t-test. For comparison of stimulated IL-6 production, a 2(group) x 4(treatment) ANOVA
was used to compare control, LPS, Ag+LPS, and Ant+LPS conditions with Bonferroni
post hoc testing to assess any potential differences between groups and within treatment
conditions. Cohen’s D effect sizes were calculated to assess if any meaningful differences
were present between CU and NU groups (180). Pearson correlation was used to assess
significant correlations present between key variables of interest. The Pearson correlation
matrix for these key variables can be seen in Appendix B.
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CHAPTER IV
RESULTS
Participants
A total of 26 participants were recruited into the study and a total of 23
participants completed all study visits. Of the three participants that were unable to
complete all study visits, two were unable to provide blood samples and the remaining
participant was excluded due to diagnosis of mononucleosis after completing the first
study visit. Twelve were NU (n=8 male; n=4 female), and eleven were CU (n=8 male;
n=3 female). The majority of participants were Caucasian (n=16) while the remaining
participants were of Hispanic/Latino (n=5), Asian (n=1) or African American (n=1)
decent. Participants did not report any current significant medical issues that would be
considered counterproductive to their participation in this study. Only two participants
reported minor current medical issues; one NU reported the presence of phenylketonuria
and one CU reported non-alcoholic fatty liver. Of the n=7 female participants who
completed the study, none were currently or had previously been pregnant. While all
female participants had previously taken birth control, only one NU was currently taking
birth control in pill form. None of the female participants had undergone surgery for total
or partial hysterectomy or undergone hormone replacement therapy. There were no
differences in the total amount of alcoholic beverages consumed on a weekly basis
between groups (3.2 ± 3.1 drinks, p=0.26; ES=0.49).
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Characteristics of Cannabis Use
All participants in the CU group met the minimum cannabis use requirement,
which was 5 cannabis uses per week or more. Information pertaining to the cannabis use
habits of the eleven CU can be found in Table 4.1. Of the eleven CU, nine (82%) were
using cannabis products daily. Participant duration of cannabis use ranged from 1-14
years, with only two CU participants reporting the use of cannabis products prior to being
16 years of age. A total of six participants in the NU group reported previous use of
cannabis products, but none of those participants reported any use of cannabis within the
past 6-months. The remaining six NU reported no prior use of cannabis products.
Table 4.1: General Cannabis Use

Days Used in the Past Week

CU
(n=11)
5.9 ± 1.6

Days Used in the Past Month

26.4 ± 5.6

Daily Uses of Cannabis: Overall

3.0 ± 1.3

Daily Uses of Cannabis: Weekday

2.8 ± 1.3

Daily Uses of Cannabis: Weekend

3.7 ± 1.8

Primary Method of Use
Method
Bong
Joint
Hand Pipe
Number (n)
5
2
2
Total Years Using Cannabis (years)
7.5 ± 3.6
Age at First Use (years)

16.8 ± 2.8

Age Started Using Cannabis >2times/month (years)

20.4 ± 6.9

Age Started Using Cannabis on Daily
or Near Daily Basis (years)

22.0 ± 6.5

Vaporizer
2
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Note: Data are presented as mean ± SD. CU = cannabis user. Values are participant
responses to the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use
Inventory. Primary method of use was defined as the method that participants used most
often when using cannabis products.
Of the n=11 CU participants, 91% (n=10) reported that their primary form of
cannabis used was marijuana in the form of flower/bud (MU), while the remaining
participant primarily used products in the form of oil concentrates. Characteristics
describing the use habits of marijuana flower/bud of MU is provided in Table 4.2.
Table 4.2: Marijuana Flower/Bud Use

Marijuana Used per Session (grams)

MU (n=10)
0.23 ± 0.12

Marijuana Used per Day of Use (grams)

0.94 ± 0.75

Marijuana Used Day Before 1st Visit (grams)

0.53 ± 0.69

Marijuana Used per Week (grams)

5.4 ± 4.2

Number of Sessions per Day of Marijuana Use

2.4 ± 1.1

Average THC Content of Marijuana Used
THC Range
10-14%
15-19%
20-24%
25-30%
Number (n)
1
4
4
1
Note: Data are presented as mean ± SD. MU = Marijuana user, defined as: cannabis that
was used in its unprocessed form, i.e., flower/bud. THC = delat-9-tetrahydrocannabinol.
Values are responses to the Daily Sessions, Frequency, Age of Onset, and Quantity of
Cannabis Use Inventory.
A total of six participants reported using cannabis in the form of concentrates at
least 25% of the time that they used, including the one individual that reported
concentrates as their primary form of use. None of these participants reported the use of
concentrates the day prior to the first study visit. When using cannabis concentrates,
individuals reported taking an average of 2.0 ± 1.3 hits per session, during an average of

41
1.7 ± 1.0 sessions per day, with a mean intake of 3.4 ± 2.9 hits per day. They also
reported using an average of 0.10 ± 0.05 grams of concentrate per day. Of the six
participants that were using cannabis concentrates, four of these individuals reported that
the concentration of THC in the products they used was at least 60%, while the remaining
two were unsure of the concentration. The use of edibles was not reported as the primary
method of use for any participants, but almost half (n=5) of the eleven CU reported that
they used edibles at least 25% of the time that they used cannabis products. The average
THC content of the edibles was 14.0 ± 6.5 mg and ranged from 10 mg to 25 mg of THC.
Physical Characteristics
There were no significant differences in age, height, body mass, BMI, body fat,
waist and hip circumference and ratio, when NU and CU were compared (Table 4.3).
While no significant difference was detected between NU and CU groups for body fat,
waist or hip circumference, there were moderate effect sizes for each variable.
Participants averaged 27.7 ± 5.5 years of age; NU ranged in age from 18-37 years old and
CU ranged from 20-39 years old. Mean BMI and body fat measures were 24.61 ± 4.30
kg/m2 and 11.2 ± 5.4% and ranged from 19.33 to 37.91 kg/m2 and 4.9 to 21.2%,
respectively.
Female participants (31.1 ± 7.1 years) were significantly older than male
participants (26.2 ± 4.1 years) and ranged from 18 to 39 and 20 to 35 years of age
respectively (p=0.04). Male participants had significantly higher systolic (p=0.03) and
diastolic (0.02) blood pressure, with an average blood pressure of 113.8 ± 10.5 / 74.1 ±
7.8 mmHg compared to 103.7 ± 7.1 / 65.1 ± 7.0 mmHg in females. Females had a
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significantly higher mean body fat percent of 17.0 ± 2.6% when compared to males with
a mean body fat percent of 8.7 ± 4.1% (p<0.001).
Table 4.3: Descriptive Characteristics and Performance

Age (years)

Overall
(N=23)
27.7 ± 5.5

NU
(n=12)
28.3 ± 6.0

CU
(n=11)
27.0 ± 5.1

Pvalue
0.58

Cohen’s
D
0.24

Height (cm)

172.90 ± 9.89

173.25 ± 10.81

172.51 ± 9.30

0.86

0.07

Mass (kg)

74.20 ± 18.85

77.33 ± 22.96

70.78 ± 13.31

0.42

0.35

BMI (kg/m2)

24.61 ± 4.30

25.42 ± 5.02

23.72 ± 3.35

0.36

0.40

Body Fat (%)

11.2 ± 5.4

12.9 ± 5.3

9.3 ± 5.0

0.11

0.72

Waist (cm)

77.0 ± 8.3

79.3 ± 10.3

74.5 ± 4.8

0.17

0.60

Hips (cm)

96.7 ± 8.10

99.0 ± 10.1

94.2 ± 4.4

0.17

0.61

Waist to Hip
0.79 ± 0.05
0.80 ± 0.05
0.79 ± 0.04
0.66
0.19
ratio
Note: Data are presented as mean ± SD. NU = non-user of cannabis; CU = cannabis user;
BMI = body mass index.
Physical Activity Habits
All participants met the inclusion criteria for weekly physical activity of at least
1.25-hours (75-minutes) of vigorous intensity activity or 2.5-hours (150-minutes) of
moderate intensity activity. There was no significant difference in the number of days or
average time engaged in vigorous or moderate intensity activity when NU and CU were
compared (Table 4.4). Overall, the number of days per week that participants engaged in
vigorous intensity physical activity ranged from 0-6 days and moderate activity ranged
from 0-6 days. Only one participant, a CU, reported not engaging in any vigorous
intensity activity. A total of four participants (NU; n=2 and CU; n=2) reported not
engaging in any moderate intensity activity. Although, CU did not statically spend less
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time walking on a daily basis (p=0.06, effect size of 0.88) CU spent significantly less
time sitting each day than NU (p<0.01), which was supported by a large effect size. There
were no sex differences between any of the self-reported measures of physical activity.
Table 4.4: Self-reported Physical Activity Within the Past Week
Overall
(N=23)
3.5 ± 1.8

NU
(n=12)
3.6 ± 1.8

CU
(n=11)
3.4 ± 1.80

P-value
0.77

Cohen’s
D
0.13

Time engaging in
vigorous activity
per day (hours)

1.5 ± 1.0

1.6 ± 0.8

1.3 ± 1.20

0.56

0.25

Days moderate
activity

3.0 ± 1.9

3.4 ± 1.8

2.6 ± 2.0

0.28

0.48

Time engaging in
moderate activity
per day (hours)

1.3 ± 1.6

1.4 ± 1.9

1.1 ± 1.4

0.57

0.25

Days walked ≥ 10minutes

5.3 ± 2.0

5.3 ± 2.0

5.3 ± 2.1

0.98

0.01

Time spent
walking (hours)

1.7 ± 1.9

2.4 ± 2.3

0.9 ± 0.8

0.06

0.88

Time spent sitting
per day (hours)

6.6 ± 2.6

8.0 ± 3.0

5.1 ± 0.7

<0.01

1.36

Days vigorous
activity

Note: Data are presented as mean ± SD. NU = non-user of cannabis; CU = cannabis user.
Responses are based on the 7-question format of the International Physical Activity
Questionnaire.
Cardiovascular and Performance Measures
There were no differences with respect to resting heart rate, systolic or diastolic
blood pressure, hydration status, or relative V̇O2 max between groups (Table 4.4). In
addition, all variables with respect to cardiovascular and performance measures
demonstrated small effect sizes (Table 4.5). Resting heart rate, systolic, and diastolic
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blood pressure ranged from 43 to 63 bpm, 90 to 128 mmHg and 56 to 84 mmHg,
respectively. All participants were considered hydrated at the time of performance
testing; with hydration measured by urine specific gravity ranged from 1.003 to 1.025.
All participants met at least two of the following four established criteria for attainment
of a true V̇O2max: 1.) Plateau in V̇O2 with increased intensity, 2.) Heart rate within 10
bpm of age predicted max heart rate (220-age), 3.) Respiratory exchange ratio greater
than 1.10, 4.) RPE ≥ 8.5 on the modified Borg scale.
There were no differences between NU and CU within sexes with respect to
resting HR, systolic/diastolic BP, urine specific gravity, relative V̇O2 max, or RPE at
termination of maximal exercise. Average resting HR for male participants was 55.8 ±
6.4 bpm and was 55.0 ± 6.6 bpm for females. Males had higher systolic (p=0.03) and
diastolic (0.02) blood pressure than females with an average of 113.9 ± 10.5/74.1 ± 7.8
mmHg and 103.7 ± 7.1/65.1 ± 7.0 mmHg, respectively. Female participants also had
significantly lower urine specific gravity of 1.007 ± 0.005 compared to males 1.015 ±
0.007 (p<0.01). V̇O2max for male participants averaged 47.8 ± 4.1 ml/kg/min and 41.1 ±
7.5 ml/kg/min in female participants. There were no significant differences between male
and female V̇O2 max (p=0.06, with Levene’s test for equality of variances=0.02). Male
V̇O2 max values ranged from 40.8 to 56.6 ml/kg/min and female V̇O2max ranged from
35.5 to 52.5 ml/kg/min. There was no difference in RPE at termination of exercise
between males (8.9 ± 0.8) and females (8.9 ± 0.7).
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Table 4.5: Resting Heart Rate, Blood Pressure, Hydration and Cardiovascular
Performance
Overall
(N=23)
55.5 ± 6.3

NU
(n=12)
55.5 ± 6.0

CU
(n=11)
55.5 ± 6.9

P-value

Cohen’s
D
0.01

Resting HR
0.99
(bpm)
Systolic BP
110.8 ± 10.6
110.2 ±
111.5 ±
0.78
0.12
(mmHg)
11.5
10.0
Diastolic BP
71.4 ± 8.4
71.2 ± 9.7
71.6 ± 7.4
0.90
0.06
(mmHg)
Urine specific
1.013 ± 0.007
1.012 ±
1.014 ±
0.56
0.26
gravity
0.008
0.007
Relative V̇O2
45.8 ± 6.1
45.4 ± 6.1
46.2 ± 6.2
0.75
0.14
max (ml/kg/min)
RPE at
8.9 ± 0.7
8.9 ± 0.9
8.9 ± 0.6
0.98
0.01
Termination
Note: Data are presented as mean ± SD. NU = non-user of cannabis; CU = cannabis user;
HR = heart rate; BP = blood pressure; RPE = Rating of Perceived Exertion.
Psychological Characteristics
None of the participants reported being hospitalized for depression within the past
6-months; however, n=4 CU participants had previously received treatment for
depression but were no-longer receiving treatment. A total of n=5 participants (n=4 CU)
reported current feelings of anxiousness in their daily lives. On average, CU had a
significantly greater total depressive score with a large effect size on the BDI-II with an
average of 5.1 ± 4.8 points compared to NU at 0.8 ± 1.0 points (p<0.01; ES=1.29). This
difference persisted when controlling for participant age and BMI (F[3,19] = 8.105,
p=0.01). Across all participants there were no correlations between total BDI-II score,
age, BMI, resting IL-6 or CRP concentration. Total BDI-II score in CU was positively
correlated to the number of times individuals used cannabis on weekend days (r=0.620,
n=11, p=0.04), but no other measures of cannabis use.
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Resting Concentrations of Markers of Inflammation
Resting concentrations of CRP were not statistically different between NU (0.87 ±
1.51 mg/L) or CU (0.78 ± 1.11 mg/L) groups (p=0.88; ES=0.07). This lack of difference
between groups with respect to CRP persisted even when controlling for age and body fat
percentage (F[3,19] = 0.075, p=0.79). There were no significant correlations between
resting CRP concentrations and age, height, mass, BMI or IPAQ generated measures of
physical activity. Within CU who used marijuana flower/bud as their primary form of
cannabis (MU; n=10), concentrations of CRP were positively correlated to total amount
of marijuana flower/bud (grams) used per week (r=0.705, n=10, p=0.02). Concentrations
of CRP were not related to any other measures of cannabis use.
Resting IL-6 concentrations were not different between NU (0.89 ± 0.71 pg/mL)
and CU (1.33 ± 1.37 pg/ml) (p=0.34; ES=0.42) and remained insignificant despite
adjusting for age and body fat percent (F[3,19] = 1.263, p=0.28). Resting concentrations
of CRP and IL-6 were positively correlated to each other (r=0.524, n=23, p=0.01). No
significant correlations existed between resting IL-6 concentrations and age, height,
mass, BMI, or physical activity habits reported on the IPAQ. Similar to CRP, resting IL-6
concentrations were positively correlated to the amount of marijuana (grams) used per
week (r=0.690, n=10, p=0.03) in MU, but not with other measures of cannabis use.
Monocyte Phenotype
The proportion (%) of monocytes circulating in the blood was not significantly
different between groups (Table 4.6). Further assessment of the distribution of the three
monocyte sub-types of classical, non-classical and intermediate monocytes, showed that
there was no difference in the percent of classical or non-classical monocytes between
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groups. However, the proportion of intermediate monocytes, which was accompanied by
a large effect size, potentially suggesting that CU had a significantly greater proportion of
intermediate monocytes compared to NU (Table 4.6). The findings on the total percent of
circulating monocytes (F[1,18] = 0.014, p=0.91), percent classical (F[1,18] = 4.401,
p=0.05), non-classical (F[1,18] = 0.023, p= 0.88) and intermediate (F[1,18] = 6.238,
p=0.02) monocytes remained consistent when controlling for participant age and body fat
percentage.
When standardizing the number of circulating monocytes per milliliter of blood,
CU had significantly higher monocytes with an effect size of 1.31 suggesting a large
meaningful difference between groups (Table 4.7). The number of monocytes per
milliliter positively correlated to participant BDI-II score (r=0.445, n=22, p=0.04), the
amount of marijuana flower/bud used the day before (r=0.744, n=10, p=0.01), and the
average number of times participants used marijuana flower/bud per day used (r=0.729,
n=10, p=0.2). The number of classical, non-classical, and intermediate monocytes per
milliliter of blood is presented in Table 4.7. Cannabis users had significantly greater
classical and intermediate monocytes per milliliter. The number of classical (r=0.448,
n=22, p=0.04) and intermediate (r=0.475, n=22, p=0.03) monocytes both positively
correlated to BDI-II score. The number of classical monocytes per milliliter did not
correlate with any measures of cannabis use. In CU, the number of intermediate
monocytes per milliliter positively correlated to the average number of times participants
used marijuana flower/bud per day (r=0.864, n=10, p<0.01), the number of hits
participants took when using cannabis concentrates (r=0.916, n=6, p=0.01) and the
amount of milligrams of THC in edibles used (r=0.934, n=5, p=0.02). Finally, the number
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of non-classical monocytes positively correlated to resting CRP (r=0.569, n=22, p<0.01),
resting IL-6 (p=0.712, n=22, p<0.01) and the amount (grams) of marijuana flower/bud
used per week.
Table 4.6: Relative Proportions of Whole Blood Monocytes
Overall
(N=22)
3.12 ± 1.55

NU
(n=11)
2.97 ± 1.23

CU
(n=11)
3.27 ± 1.87

Pvalue
0.63

Cohen’s
D
0.56

Total Monocytes
(%)
Classical
76.93 ± 8.48 79.49 ± 6.74 74.37 ± 9.54
0.16
0.63
(%)
Non-Classical
12.74 ± 7.14 13.82 ± 6.12 11.65 ± 8.18
0.49
0.31
(%)
Intermediate
10.11 ± 7.77 6.33 ± 4.92 13.89 ± 8.43
0.02
1.12
(%)
Note: Data are presented as mean ± SD. NU = non-user of cannabis; CU = cannabis user.
Classical, Non-classical, and Intermediate sub-types were determined by relative
expression of cell surface CD-14 and CD-16 expression using flow cytometry.
Table 4.7: Number of Monocytes per Milliliter of Whole Blood
Overall
(N=22)
4.12x105 ±
1.69x105

NU
(n=11)
3.23x105 ±
1.20x105

CU
(n=11)
5.08x105 ±
1.63x105

Pvalue
0.01

Cohen’s
D
1.31

Classical
Monocytes per
mL of blood

3.15x105 ±
1.30x105

2.56x105 ±
0.97x105

3.77x105 ±
1.36x105

0.02

1.04

Non-Classical
Monocytes per
mL of blood

4.95x104 ±
3.50x104

4.27x104 ±
2.38x104

5.72x104 ±
4.38x104

0.31

0.41

Monocytes per
mL of blood

Intermediate
4.72x104 ±
2.32x104 ±
7.29x104 ±
0.01
1.26
Monocytes per
4.69x104
2.18x104
5.19x104
mL of blood
Note: Data are presented as mean ± SD. NU = non-user of cannabis; CU = cannabis user.
Classical, Non-classical, and Intermediate sub-types were determined by relative
expression of cell surface CD-14 and CD-16 expression using flow cytometry.
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Lipopolysaccharide Stimulated IL-6 Production
There were no group or treatment effects with respect to the LPS induced IL-6
release over a 24-hour period (F[1,63] = 0.332, p=0.567) (Figure 4.1). Despite adjusting
for participant age, BMI, body fat percent and monocyte percent, there were still no
differences present in the amount of LPS induced IL-6 release. The relative amount of
IL-6 released per monocyte (Figure 4.2) was not significantly different between groups
within treatment conditions. The number of non-classical monocytes per milliliter
significantly correlated to the amount of IL-6 released in the LPS (r=0.681, n=22,
p<0.01), Ag+LPS (r=0.757, n=22, p<0.01) and Ant+LPS (0.681, n=22, p<0.01) treatment
conditions. The number of classical and intermediate monocytes per milliliter did not
correlate to the amount of IL-6 release in any of the treatment conditions. The resting
concentrations of IL-6 were strongly correlated to the amount of IL-6 released in in each
of the LPS stimulated conditions LPS control (r=0.569, n=23, p<0.01), Ag+LPS
(r=0.641, n=23, p<0.01) and Ant+LPS (r=0.601, n=23, p<0.01) conditions.

Figure 4.1. Lipopolysaccharide Stimulated IL-6 Release. Data are depicted as mean ±
SD. LPS=Lipopolysaccharide, Ag+LPS=CB2 agonist with LPS, Ant+LPS=CB2
antagonist with LPS. Control samples were unstimulated with LPS.
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1.0

Non-User

Relative IL-6 Released/Monocyte

User
0.8

0.6

0.4

0.2

0.0
LPS

Ag+LPS

Ant+LPS

Figure 4.2. Relative Lipopolysaccharide Stimulated IL-6 Released per Monocyte. Data
are depicted as mean ± SD. LPS=Lipopolysaccharide, Ag+LPS=CB2 agonist with LPS,
Ant+LPS=CB2 antagonist with LPS. Stimulated concentrations of IL-6 were
standardized to the number of monocytes per participant.
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CHAPTER V
DISCUSSION AND CONCLUSIONS
This was the first study to assess the effects of chronic cannabis consumption in
individuals that regularly engage in physical activity on circulating monocyte phenotype
and immune response to LPS. The hypothesis in response to our first specific aim was
supported, as there was no difference in total circulating blood monocytes between NU
and CU, but CU demonstrated significantly elevated concentrations of intermediate
monocytes when compared to NU. The second specific hypothesis of this study stated
that resting concentrations of serum CRP and IL-6 would be greater in CU, which was
rejected as there were no differences in the circulating concentrations of these two
inflammatory markers. In assessment of LPS induced IL-6 release from whole blood
samples, there was no difference found between the total amount of IL-6 released
between NU and CU in any of the treatment conditions. Finally, the number of
intermediate monocytes per milliliter was positively associated with the number of times
CU were using marijuana flower or bud products per day.
Characteristics of Cannabis Use
The inclusion criteria for cannabis use in this study required at least 5 cannabis
uses a week for the past 6-months. All CU participants exceeded this criterion using, on
average, slightly less than 6-days per week with an average number of cannabis uses of 3times per day. This equates to an average of slightly less than 18 uses per week. Further,
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participants reported using an average of 26.4 ± 5.6 days over the past 30 days. In the
present study, CU were using an average of 1.4 more days per week and almost twice as
many times per day compared to a previous study performed by our lab aimed at
evaluating circulating bio-markers of neural and immune health in physically active
cannabis users and non-users (181). The cannabis users from this previous study were
using an average of 1.67 ± 0.72 uses per day and reporting an average of 18 days of use
within the last 30 days (181); however, it should be mentioned that the inclusion
requirement for the aforementioned study was only one use per week for the past 6months. It is likely that this difference may have led to the disparity in reported cannabis
use.
In the current study, all participants reported that their primary method of use was
through inhalation with 46% using a bong, 18% using a joint, 18% using a hand pipe, and
18% using vaporizer. Comparing this information to two previous studies performed in
our lab assessing physically active individuals using cannabis products, all but one
participant, who used edibles, also used cannabis primarily through inhalation (31, 181).
Additionally, a survey study published from our lab found that 80% of individuals that
used cannabis with exercise reported that their primary method of use was also through
inhalation (30). Even though other methods of use including topicals, tinctures and
edibles are other options for use, it appears that, for someone who is physically active,
inhalation is the primary method of choice. This could be due to the fact that the use of
cannabis through inhalation increases blood concentrations of cannabinoids, like THC,
more rapidly when compared to edibles (182).
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The majority (80%) of participants reported that the average content of their
marijuana flower or bud was 15 to 24% THC. This reported content of THC reflects a
concentration range that is recreationally available in most commercial cannabis
dispensaries (183, 184). Only one individual reported average marijuana THC content
between 10-14% and another individual reported average marijuana THC content
between 25-30%. In addition, of the four participants that claimed to know the THC
content of their cannabis concentrates, no one reported a THC content less than 60%
which is similar to what has been measured previously (183); however, it is important to
note that the participant reported THC percentages might not be reflective of the actual
THC content of the product. More specifically, THC concentrations may vary over time
(183, 185), and the reported contents of cannabis products may be inaccurately labeled
(186) as well as to vary between strains (183). The inconsistency in the self-report of
cannabis product THC/cannabinoid content, cannabinoid content changes over time, and
labeling inaccuracies are major factors that should be better controlled for in future
studies.
Recently, there has been increased interest in the use of cannabis by physically
active individuals. One study from our lab found that 90.5% physically active
individuals, who reported using cannabis in conjunction with structured exercise, were
using cannabis products at least once per week, with nearly 69% using on a daily basis
(30). In a second survey study in individuals who were engaging in an average of 160minutes of aerobic exercise a week, individuals reported using cannabis an average
number of 5.5 days per week (187). In the present study, all participants were required to
be physically active and reported using cannabis products at least once per week with
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82% of participants using on a daily basis. This suggests that the CU participants in this
study should be classified as heavy users. It is important to note that while 91% of CU
had used cannabis products the day prior to testing, none reported that they were
currently high on the DFAQ-CU, as they were specifically asked to refrain from cannabis
use for at least 12-hours prior to testing.
Physical Characteristics
Overall average BMI was 24.61 kg/m2, which would place individuals in this
study within normal ranges (188). While there was no significant difference between
groups with respect to BMI, it is important to note that 3 participants in NU and 3 in CU
fell into the overweight or obese BMI categories. Average NU BMI of 25.42 kg/m2
classified this group as overweight, while average CU BMI of 23.72 kg/m2 were
considered normal (188). Interestingly, BMI within individuals using marijuana flower or
bud was positively associated with the amount of marijuana used per day, but no other
correlations between BMI or cannabis use were present. Prior research has reported
mixed effects with respect to BMI and cannabis use. In high school teens and HIVpositive patients using cannabis, there were no reported relationships between BMI and
cannabis use (189, 190). Yet, in support of our current findings, multiple studies have
reported that prolonged cannabis use was associated with lower BMI and decreased
likeliness to be obese (191-193). In contrast, there was no difference in average BMI or
group BMI classification between cannabis users or non-users who were equally
physically active (181). It should be noted that while BMI is a simple way to provide
insight into the body size of the general population it is often considered inaccurate in
athletic populations as it does not take fat or fat-free mass into consideration.
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While there was no significant difference between groups with respect to body fat
percent, there was a moderate effect size accompanying this variable suggesting that
there was a moderately meaningful difference present between groups. A combined
average body fat percent for the present study of 11.2 ± 5.4% is significantly lower than
the average body fat of male and female cannabis users and non-users of 28% observed
in a study assessing the metabolic health, total body fat and abdominal fat distribution
(141). Male participants had an average body fat of 8.7 ± 4.1%, and with an average age
of 26.2 years old, these participants would be classified in the 85-90th percentile for body
fat percentage of similarly aged males (188). However, the average values for male body
fat percentage of the present study were relatively lower than those observed in a
previous study which reported an average body fat of 11.9 ± 5.8% in physically active,
college aged, male cannabis users and non-users (31). The female participants in the
present study had an average body fat of 17.0 ± 2.6% and, with an average age of 31.1
years old, corresponds to the 80-85th percentile for body fat percentage of similarly aged
females (188). While the aforementioned study by Muniyappa et al. 2013 described no
difference in total body fat when comparing cannabis users to non-users, which is similar
to our study, authors reported that cannabis users had significantly lower total abdominal
fat and subcutaneous abdominal fat as measured by magnetic resonance imaging (141).
While our study did not measure abdominal fat area or subcutaneous fat area, the average
skin-fold thickness at the abdominal site was 33% lower (p=0.04) in CU, which was
accompanied by a large effect size of 0.93. Despite these findings, there were no
significant relationships between abdominal skin-fold thickness and measures of cannabis
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use. This effect warrants deeper exploration into the possible physiological effects that
may be leading to this difference.
Physical Activity Habits
The American College of Sports Medicine recommends that individuals engage in
at least 2.5-hours of moderate physical activity per week or at least 1.25-hours of
vigorous physical activity per week (188). All participants exceeded these
recommendations and were engaged in an average of 5.01-hours of moderate physical
activity and 5.6-hours of vigorous physical activity on a weekly basis. There was no
observed difference in the days, duration, or overall average time that NU and CU
engaged in either moderate or vigorous physical activity. These values are comparable to
the self-reported total amount of hours of moderate (5.2-hours) and vigorous (5.5-hours)
physical activity engaged in by male cannabis users and non-users in a previous study
(31). On average, CU in the present study engaged in a total of 8.6 hours of moderate or
vigorous activity per week. This was is significantly greater than the total amount of
moderate or vigorous physical activity that was reported by physically active cannabis
users in two recent survey studies of 4.3 and 6.7 hours per week (30, 187).
Previous research on cannabis use and sedentary activity has provided mixed
findings and has mostly focused on the youth or young adult populations. One recent
study found that in adolescents aged 12 to 15 years old, more frequent use of cannabis
was associated with increased sedentary activity (194), but in a similarly aged population
of 14-16-year-old adolescents, there was no relationship between these individuals with
respect to their cannabis use or sedentary behavior (195). In another recent study, authors
reported that in emerging, young adults, the frequent use of cannabis was associated with
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an increased likelihood of meeting physical activity requirements (191). A self-reported,
survey-based finding that assessed physical activity habits of adults who used cannabis
reported that participants who used cannabis with exercise engaged in significantly
greater minutes of physical activity per week compared to cannabis users who did not use
cannabis with their exercise (187). In our study, we found that our physically active
cannabis users spent 37% less time sitting per day when compared to non-users. Given
that there was no difference in the amount of time CU spent engaging in moderate/
vigorous activity or walking on a daily basis, it is possible that CU spend more time
standing or sleeping on a daily basis or engage in more intermittent light activity. Further
research is needed assessing the activity habits of cannabis users throughout the entire
day with more accurate, real-time, objective measures.
Cardiovascular and Performance Measures
The acute use of cannabis products increases resting heart in adults and
adolescents (196-199). There is additional support that even the chronic use of cannabis
alters the sympathovagal balance, with cannabis users displaying increased heart rate
variability compared to individuals that were matched for age and BMI who were not
using illicit drugs or pharmaceuticals (200). While the acute use of cannabis on resting
heart rate has been assessed in multiple studies, there were no differences in NU and CU
resting heart rate in the present study. This is conflicting with data previously reported by
our lab in which physically active male and female cannabis users had significantly
higher resting HR than NU (181) but is in support of our previous findings in physically
active male cannabis users and non-users (31).
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There are mixed effects of acute cannabis use on systolic blood pressure with both
increases (201) and no-changes (198) observed; however, in both of these studies,
diastolic blood pressure increased immediately following use (198, 201). We have not
observed any differences in our lab with respect to either systolic or diastolic blood
pressure (31, 181). The average systolic blood pressure of 110.8 mmHg and diastolic
blood pressure of 71.4 mmHg would place them into the normal classifications of 100119 mmHg and 60-79 mmHg, respectively (202).
According to ACSM standards, the male participant average V̇O2 max in the
present study would place them into the excellent category for V̇O2max based on a mean
age of 26.2 years and V̇O2 max of 47.8ml/kg/min (188). Female participants would also
be categorized in the excellent category based on a mean age of 31.1 years and V̇O2 max
of 41.1ml/kg/min (188). There were no participants who received a classification lower
than “good,” which would be considered above average in relative terms (188). In
comparison to a previous study in our lab which explored V̇O2max in male and female
chronic cannabis users and non-users, the mean V̇O2 max in the present study was
significantly lower compared to a mean of 50.3 ± 7.4ml/kg/min (181). Despite this
difference, there was no difference between NU and CU in the present study. In the two
other studies assessing cardiorespiratory fitness in physically active cannabis users and
non-users, findings from the current study are consistent with both studies with no
reported difference in cardiorespiratory performance in cannabis users or non-users not
currently under the influence of cannabis (31, 181). In a more acute exercise setting,
cannabis inhalation prior to a maximal cycling test, revealed no difference in V̇O2 max in
cannabis and placebo trials (154). The results of this study may no-longer be applicable,

59
as the cannabis flower/bud currently available at recreational dispensaries has an average
THC content of 15 to 24% which is significantly greater than the 1.7% THC cannabis
participants smoked in their in their study (183, 184).
Psychological Characteristics
Previous research on depressive score measured by the BDI-II in physically active
cannabis users has not detected differences when cannabis users were compared to nonusers (181). In the present study, CU had a significantly higher average BDI-II score
compared to NU even after controlling for age and BMI, and BDI-II score. Additionally,
scores correlated to the frequency of cannabis usage on weekend days. Four participants
in the CU group reported that they had received treatment for depression in the past,
however, none of these participants reported that they were currently suffering from
depression nor had they been hospitalized for depression in the past six-months or
currently receiving treatment. In another study conducted in our lab, physically active CU
had significantly lower circulating brain derived neurotrophic factor (BDNF), which was
negatively correlated to total BDI-II score and positively correlated to CRP (181).
In recent years, cannabis use has been associated with an increased incidence of
depression in adolescents (203) and frequent cannabis users (191, 204). Further, in
individuals prescribed opioids for pain, depression positively correlated to self-reported
percent of THC and CBD in cannabis products, particularly those high in CBD (205),
however, it was unclear in this study if the increase in depressive symptoms associated
with cannabis use were the result of cannabis use itself or the result of an interaction
effect between the co-use of opioids and cannabis. One possible explanation for the
observed effects of cannabis on depression could be the result of the interaction between
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CBD and the serotonin 1a (5-HT1a) receptor. The non-intoxicating cannabinoid, CBD, is
a moderate agonist of the 5-HT1a receptor, displacing [3H]8-OH-DPAT, which is
another known agonist of the receptor in a concentration dependent manner (206).
Similar to the CB1 and CB2 receptors, the 5-HT1a receptor is a 7-transmembrane alphahelical G-protein coupled receptor that inhibits activation of adenylyl cyclase (207). Both
dysfunction and dysregulation of the 5-HT1a receptor have been implicated as an
underlying cause in depressive disorders (207, 208). Consequently, it is possible that the
chronic use of cannabis products causes disruption and dysregulation of the 5-HT1a
receptor leading to increases of depressive symptoms. However, it is still unclear if the
chronic use of cannabis products is leading to these increased depressive symptoms or
depressive symptoms are leading to cannabis use.
Resting Concentrations of Markers of Inflammation
The average resting concentration for circulating CRP in the present study was
not significantly different between groups and the group averages would place them both
at low risk for cardiovascular disease (CVD) (14). These findings contradict previous
research from our lab in which average CRP concentrations placed cannabis users at
moderate risk for CVD and non-users at low risk for CVD (31, 181). While there was no
relationship in the previous studies with respect to CRP and cannabis use, the present
study found that there was a positive relationship between CRP and the amount of
marijuana used per week in individuals using marijuana flower or bud. Although the
present study was cross-sectional in design, results may be similar to a longitudinal study
in which, over an 8-week treatment period, patients suffering from Crohn’s disease who
used cannabis did not have any changes or differences in pre to post CRP concentrations
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compared to a placebo control (170). However, a more recent epidemiological study
using the U.S. National Health and Nutrition Examination Survey data, found that the use
of cannabis within the past 30-days was associated with lower concentrations of CRP
than those who had not used cannabis within that same time frame (32). Although these
results are intriguing, the authors did not account for participant physical activity status.
It is also possible that there is no observable difference with respect to CRP between
physically active CU and NU because regular exercise acts powerfully to decrease
circulating CRP (18, 19). This physical activity effect may be eliminating the difference
in CRP observed within the general population.
It is important to note that no participants had CRP concentrations greater than 10
mg/L, which suggests that none of the participants were experiencing an acute infection.
The majority of participants (78%) were classified as low risk for cardiovascular disease
based on circulating CRP. Three individuals, two NU and one CU, were classified as
moderate risk and two other participants, one NU (5.51 mg/L) and one CU (3.96 mg/L),
were classified as high risk. Finally, when compared to the general population average
CRP concentration of 3.9 mg/L, both groups were significantly lower than the national
average. This effect may be attributable to the physical activity habits of the subjects in
the present study, which was discussed previously (32).
Circulating CRP and IL-6 concentrations are related (13) with CRP production
being dependent on IL-6 (13, 84). Therefore, it is not surprising that a significant,
positive relationship between CRP and IL-6 concentrations was observed when groups
were combined in the current study. Even though a positive relationship was present
between the amount of marijuana flower/bud used per week and resting concentrations of
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IL-6, this trend did not result in a significant difference in IL-6 concentrations between
NU and CU groups. This result supports previous findings from our lab in which
physically active cannabis users and non-users had an average resting concentration of
1.26 pg/mL, which was similar to the total participant average of 1.10 pg/mL, which was
observed in the present study (181). Furthermore, a separate study observed no
differences in IL-6 concentrations when recent, previous and never users of cannabis
were compared (209). Conversely, in another study, where activity status was not
accounted for, the long-term use of only cannabis was related to lower concentrations of
circulating IL-6 compared to a non-user group and a group of individuals who used
cannabis in conjunction with other drugs (210). In comparison to the values reported by
Keen et al. 2014, the average IL-6 values of participants in our study was 1.10 pg/mL
which is significantly lower than the group average for both the only cannabis use and the
non-user group of 2.20 ± 1.93 pg/mL and 3.73 ± 6.28 pg/ml respectively (210). The longterm effects of exercise have produced mixed effects on resting IL-6. Some studies report
no effect of long-term exercise training on resting IL-6 (211, 212) while others have
observed a reduction in circulating IL-6 (213, 214). Some suggest that this effect may be
dependent on the presence of the SNP-174C, IL-6 gene variant (214). Given all of these
findings, it is possible that the immune modulatory effects of sustained exercise are
greater than those of the chronic use of cannabis and nullified any possible observable
effects between groups in this study.
Monocyte Phenotype
To the researcher’s knowledge, this is the first study to describe circulating
monocyte populations in healthy participants that are using cannabis. Chronic cannabis
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users displayed altered monocyte phenotype and count compared to non-using
participants. Specifically, CU had a significantly greater relative percent of intermediate
monocytes. In healthy individuals, the expected percent of intermediate monocytes
circulating in the blood is 5% (37). Cannabis users in this study had nearly three-times
the expected percent of intermediate monocytes at 13.8% and had more than double the
percent of NU at 6.33%. This difference in the relative percent of intermediate monocytes
was supported by a large effect size between groups. Further, when standardizing the
number of intermediate monocytes per milliliter of blood, CU had a significantly greater
number of intermediate monocytes when compared to NU, which was also accompanied
by a large effect size. These results suggest that CU have a significantly greater relative
percentage of intermediate monocytes and a greater number of intermediate monocytes
per milliliter. In terms of relating cannabis use to the number of intermediate monocytes
per milliliter of blood, the number of hits per day of cannabis concentrates and the THC
content of edible cannabis products was positively correlated to the number of
intermediate monocytes in CU; however, both of these correlations are based on small
sample sizes of n=6 and n=5, respectively, limiting the validity of these observations.
Yet, in the 10 individuals that reported using marijuana flower or bud, the number of
times these participants used per day was positively associated with the number of
intermediate monocytes per milliliter. Previous research observed that the administration
of THC reduced monocyte ability to differentiate (34, 215). Intermediate monocytes
display functions and cell surface markers of classical and non-classical monocytes. The
increased number of intermediate monocytes could be the result of THC limiting the
ability of chronic user monocytes to fully differentiate into either the classical or non-
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classical sup-populations. Finally, even though previous research has related the number
of intermediate monocytes to increased risk for chronic disease including CVD, there was
no correlation between the number of intermediate monocytes and the resting
concentrations of either CRP or IL-6.
The findings from the present study conflict with previous results in which
cannabis use was associated with a significant reduction of CD16 + monocytes in
individuals diagnosed with HIV (34, 216). However, HIV is an immunocompromising
disease, and, in that same study, HIV infected non-users had a significantly greater
number of CD16+ monocyte when compared to both the non-HIV infected, non-cannabis
user control group and the HIV infected cannabis users (34). In that study, there was no
non-HIV infected, cannabis user group so it is plausible that in a diseased population, like
those with HIV, cannabis use suppresses CD16+ monocyte numbers, but may promote
CD16+ monocyte numbers in a relatively healthy population. Across all participants in
the present study, the average percent of circulating classical monocytes, which was 77%,
was slightly below the expected norm of 85% in a healthy population (37). However,
when accounting for classical monocyte group average percentages, NU were closer to
the expected norm at 80% while CU were still significantly lower at 74%. Although, CU
were below the expected norm with respect to percent classical monocytes, there was no
difference between NU or CU groups.
Clinically, the average number of circulating monocytes per milliliter of 4.12 x
105 is similar to that reported in college aged males and females of average physical
activity status (3.60 x 105 cells per milliliter) and physically active females (3.74 x 10 5
cells per milliliter) (110, 217). When controlling for monocytes per milliliter, CU had
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significantly more classical monocytes when compared to NU, which was accompanied
by a large effect size between groups. Similar effects have been reported when heavy
cannabis users were compared to non-users (216). In our study, we believe the reported
differences in the number of classical monocytes per milliliter are most likely the result
of CU also having a significantly greater number of total monocytes per milliliter. When
the number of classical monocytes was relativized with the other two monocyte
populations, this difference was no-longer present. Further, the large effect size that was
observed between the number of classical monocytes per milliliter between groups was
absent in the relative percent of classical monocytes. It is difficult to ascertain whether
this finding is consistent with previous research as the numbers of circulating CD14++
monocytes in HIV-infected cannabis users was not presented or discussed (34). The nonclassical monocytes were the only sub-population that was not different between NU and
CU groups in terms of either relative percent or the number of cells per milliliter. In spite
of this, our findings with respect to classical and intermediate monocytes suggest that
there are significant alterations in monocyte phenotype between NU and CU.
Lipopolysaccharide Stimulated IL-6 Production
Previous research has shown that acute treatment with cannabinoids like THC and
CBD results in immune suppressive effects on pro-inflammatory cytokine production in
response to an immune stimulus (167). In the 2010 study, authors used a concentration of
1µM CBD to pretreat BV-2 microglial cells, which was the same concentration of the
CB2 agonist and antagonist used in our study, prior to stimulating cells with LPS. The
pretreatment with CBD resulted in a 25% decrease in stimulated IL-6 release compared
to their LPS stimulated control (167). This CBD induced suppression of IL-6 was not
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observed in the present study as there was no differences in LPS induced IL-6 production
in either CU or NU groups when pretreated with the either the CB2 agonist or antagonist.
This lack of differences in stimulated IL-6 persisted despite standardizing for the number
of total monocytes per milliliter. It is possible that this response may be the result of time
course dependent effects. For example, in the aforementioned study, control and
stimulated samples were collected 4-hours post addition of LPS in which noncannabinoid stimulated samples had significantly greater concentrations of IL-6 (167).
Yet, in the present study, stimulated supernatant was collected 24-hours post LPS
stimulation. Consequently, it is plausible that CB2 agonists like CBD or JWH-015 have
acute suppressive effects, and the longer samples are exposed to LPS, the more likely
these samples are able overcome these suppressive effects.
Another explanation for the lack of difference between stimulated treatments and
groups could be the lack of difference in both the circulating percent and the number of
non-classical monocytes per milliliter. When all participants were considered, only the
non-classical monocyte subtype was positively associated with the total amount of IL-6
release in any of the conditions. Classical monocytes are considered largely phagocytotic
with limited inflammatory attributes; while intermediate monocytes display moderate
functions of both classical and non-classical sub-sets. It is largely the non-classical
monocytes that are attributed to pro-inflammatory cytokine release (218-220). The
number of classical and intermediate monocytes was significantly greater in CU
compared to NU, but there was no difference in either the percent or number per milliliter
of non-classical monocytes. This lack of difference in the intermediate monocyte sub-set
may be accountable for the lack of difference in LPS induced cytokine release. Further,
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there is a lack of literature pertaining to the distribution of both the CB1 and the CB2
receptor expression between the different monocyte populations. If the CB2 receptor is
expressed to a lesser extent in non-classical monocytes, it may result in a reduced
response to LPS.
Limitations
This study was cross-sectional in design and compared physically active NU to
physically active CU. As such, we cannot be certain that reported differences in
monocyte phenotype and number are strictly the result of cannabis use status. All
participants met the inclusion criteria for use and non-use status; however, half of the
participants in the NU group had previously used cannabis to some extent throughout
their life. It is possible that the previous use status of these participants could be
confounding factors of these results. Further, while all CU were primarily using cannabis
by inhalation methods, there was variation as to the primary method of inhalation as well
as their secondary method of use. The type of cannabis product, the frequency of use, and
timing of cannabis use was also not standardized across CU. Future research assessing
these parameters should aim to standardize these variables to minimize variation between
participants in terms of cannabis use. Further, in the future, research should focus on
comparing not only physically active NU and CU but also non-physically active NU and
CU. This will help elucidate if similar observations are observed regardless of physical
activity status causes different effects.
At the time of this study, the phytocannabinoids THC and CBD were still
considered schedule one substances and researchers were forced to use synthetically
derived cannabinoids to mimic the effects of the aforementioned phytocannabinoids.
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These synthetic cannabinoids are designed specifically to stimulate or suppress activation
of the CB2 receptor; however, THC and CBD act on more than just the CB2 receptor. In
the future, not only should the effects of purified CBD and THC extracts be fully
explored, but the effects of full spectrum cannabis extracts containing all the active
ingredients within the cannabis plant may be valuable. This approach would be more
reflective of products available on the market for recreational and medicinal
consumption. Finally, immune stimulations in this study were reflective of how an
immune response would proceed in response to non-sterile inflammation, like an
infection. Future studies should also assess the immune response in the presence of a
sterile stimulus, like adenosine, that would be reflective of tissue damage like resulting
from trauma or intense exercise.
Conclusions
Findings from this study provide novel insight into the effects of chronic cannabis
use in physically active individuals. Although there were no differences between CU and
NU groups with respect to age, mass, height, body fat percent, BMI, resting heart rate,
blood pressure or V̇O2max there was evidence to suggest there might be differences in
the fat distribution, with CU having a significantly lower abdominal skinfold thickness.
Cannabis users displayed altered monocyte phenotype compared to NU, with CU
displaying more than a 2-fold increase in the relative circulating percentage of
intermediate monocytes. In addition to altered monocyte phenotype, CU had significantly
greater total monocytes, classical and intermediate monocyte sub-populations per
milliliter. Non-classical monocytes were the only cell population to be similar in both
groups in terms of both relative percent and cells per milliliter. It is believed that this lack

69
of difference in the non-classical cell population is potentially accountable for the lack of
difference observed in LPS stimulated IL-6 release in the presence of CB2 agonist and
antagonist pre-treatment. In conclusion while previous research suggests that individually
exercise and cannabis use are associated with beneficial effects on monocyte phenotype
and immune function there is not a combinatorial effect between the two. Monocyte
phenotype and count did differ between physically active NU and CU, but this was not
related to changes in resting concentrations of inflammatory markers CRP and IL-6, nor
did it alter whole blood LPS stimulated IL-6 release.
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